

**PHARMACOLOGY BIOCHEMISTRY
&
BEHAVIOR**

Index to

VOLUME 25 1986

SUBJECT INDEX

- Abrupt refeeding, 623
 food deprivation
 phentermine
 self-administration
 Acarbose, 491
 dietary starch
 intestinal distention
 Acetylcholine release, 943
 drug interactions
 locomotor activity
 N-methyl aspartate
 Acoustic startle, 1175
 amphetamine
 cocaine
 cross-tolerance
 habituation
 phencyclidine (PCP)
 sensitization
 tolerance
 Acute administration
 aggression, 1195
 antipsychotic drugs, 897
 chronic administration, 897, 1195
 magnesium, 1195
 spontaneous chewing movements, 897
 tardive dyskinesia, 897
 tolerance, 1195
 Acylating phencyclidines, 51
 calcium antagonist binding
 drug interactions
 Adenosine receptors, 769
 hypothermia
 inbred strains
 locomotor activity
 methylxanthines
 theobromine
 Adenylate cyclase, 223
 ³H-cyclic AMP
 norepinephrine (NE)
 REM sleep deprivation
 Adipsia, 17
 amphetamine
 anorexia
 dopamine terminal area
 Adjunctive consumption
 alcohol, 1159, 1163
 drinking, 1159, 1163
 extinction, 1159, 1163
 lithium, 1159, 1163
 shock, 1163
 stress, 1163
 water, 1159
 Adrenal cortex, 753
 adrenocorticotrophin 1-24 (ACTH 1-24)
 corticosterone synthesis
 steroidogenesis
 alpha₂-Adrenergic antagonists, 155
 amphetamine
 in vivo
 locomotor activity
 stereotypy
 Adrenergic receptors
 clonidine, 989
 continuous infusion, 989
 dopamine receptors, 763
 drug interactions, 989
 marijuana, 763
 naloxone, 989
 opiate abstinence syndrome, 989
 perinatal exposure, 763
 tyrosine hydroxylase activity, 763
 Adrenoceptors, 329
 antidepressants
 ³H-dihydroalprenolol binding
 ³H-prazosin
 REM sleep deprivation
 alpha Adrenoceptors, 903
 cerebral cortex
 cold exposure
 α₁-Adrenoceptors, 743
 β-adrenoceptors
 functional sensitivity
 noradrenergic denervation
 N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4)
 β-Adrenoceptors, 743
 α₁-adrenoceptors
 functional sensitivity
 noradrenergic denervation
 N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4)
 Adrenocorticotrophin 1-24 (ACTH 1-24), 753
 adrenal cortex
 corticosterone synthesis
 steroidogenesis
 Age differences
 antinociception, 599
 avoidance conditioning, 673
 cats, 359
 locomotor activity, 599
 maze learning, 673
 memory, 673
 morphine, 599
 phencyclidine (PCP) metabolites, 359
 scopolamine, 673
 tolerance, 359
 Aggression
 acute administration, 1195
 bull breeds, 71
 chronic administration, 1195
 limbic system, 71
 magnesium, 1195
 neurotransmitter amino acids, 71
 tolerance, 1195
 Alcohol
 adjunctive consumption, 1159, 1163
 drinking, 1159, 1163
 extinction, 1159, 1163
 lithium, 1159, 1163
 shock, 1163
 stress, 1163
 water, 1159
 Alcohol dehydrogenase, 1013
 alcohol elimination rate
 alcohol-preferring rats
 free-choice drinking
 metabolic tolerance
 Alcohol elimination rate, 1013
 alcohol dehydrogenase
 alcohol-preferring rats
 free-choice drinking
 metabolic tolerance
 Alcohol-preferring rats, 1013
 alcohol dehydrogenase
 alcohol elimination rate
 free-choice drinking
 metabolic tolerance
 Alternation, 29
 amphetamine
 locomotor excitation
 perseveration
 Ambient temperature, 667
 chronic administration
 ethanol
 hypothermia, ethanol-induced
 tolerance
 Amnesia
 anisomycin, 567
 cycloheximide, 567
 drug interactions, 567, 925
 hemicholinium-3, 925
 naloxone, 567
 passive avoidance, 567
 piracetam-like compounds, 925
 shuttle avoidance, 567
 Amphetamine
 acoustic startle, 1175
 adipsia, 17
 alpha₂-adrenergic antagonists, 155
 alternation, 29
 anorexia, 17
 anorexia, drug induced, 711
 cocaine, 1175
 cross-tolerance, 1175
 dopamine depletion, 1307
 dopamine terminal area, 17
 eating, 1149
 eating motivation, 123
 fenfluramine, 123
 habituation, 1175
 hyperactivity, drug induced, 711
 in vivo, 155
 lesions, 6-hydroxydopamine (6-OHDA), 1307
 lesions, substantia nigra, 1307
 locomotor activity, 115, 161, 1149
 locomotor excitation, 29
 metabolic rate, 161
 naloxone, 123
 naltrexone, 123
 nucleus accumbens, 1149
 perseveration, 29
 phencyclidine (PCP), 1175
 phenylethylamine (PEA), 711

- recovery, 1307
- rotation, 1307
- satiety, 123
- sensitization, 1175
- stereotypy, 155
- tolerance, 1175
- Amphetamine-induced hyperactivity, 919
 - estrogen
 - time-dependent modulation
- Amphetamine self-administration
 - brain catecholamines, 1027
 - L-tryptophan, 849
 - L-tyrosine, 1027
- d-Amphetamine
 - bin analysis, 145
 - inter-response time, 145
 - monkeys, 145
 - Sidman avoidance schedule, 145
 - simultaneous brightness discrimination, 939
 - two stage administration, 939
- Analgesia
 - benzodiazepine receptors, 215
 - classical conditioning, 1201
 - environmental specific cues, 1201
 - habituation, 1201
 - morphine, 215, 1201
 - snails, 1201
 - stress, 1201
 - tolerance, 1201
- Analgesia, stress-induced, 171
 - cold water swim
 - hyperphagia
 - hypothermia
 - muscarinic agents
 - pain
- Analgesiometry, 481
 - ear-withdrawal
 - rabbits
- Anesthesia, 641
 - antinociception
 - cardiovascular system
 - [D-Ala²]-methionine enkephalinamide (DALA)
 - renal sympathetic nerve
- Angiotensin converting enzyme (ACE) activity, 953
 - aspartic acid
 - brain asparaginase
 - morphine dependent rats
 - naloxone
 - plasma cortisol level
- Anhedonia
 - duration of response, 615
 - force of response, 615
 - haloperidol, 1231
 - licking, 219
 - partial reinforcement extinction effect, 1231
 - pimozide, 219, 615
 - response rate, 615
 - reward omission, periodic, 1231
 - sucrose concentration, 219
 - water reinforcement, 1231
- Animal model, 297
 - Huntington's disease
 - locomotor hyperactivity
 - neural transplants
- Anisomycin, 567
 - amnesia
 - cycloheximide
 - drug interactions
- naloxone
 - passive avoidance
 - shuttle avoidance
- Anorexia
 - adipsia, 17
 - amphetamine, 17
 - dopamine terminal area, 17
 - eating, 99
 - fenfluramine, 967
 - FG 7142, 99
 - gastrointestinal tract, 967
 - grooming, 99
 - hyperphagia, 99
 - locomotor activity, 99
 - midazolam, 99
 - opioid peptides, 967
- Anorexia, drug induced, 711
 - amphetamine
 - hyperactivity, drug induced
 - phenylethylamine (PEA)
- Anticonvulsant effects, 1059
 - bicuculline
 - drug interactions
 - GABA_A receptors
 - maximal electroshock
 - pentobarbital
 - phenobarbital
 - picrotoxin
 - seizures
- Antidepressants
 - adrenoceptors, 329
 - ³H-dihydroalprenolol, 329
 - escape deficit, 1
 - inescapable shock, 1
 - intraspecies behavior, 515
 - learned helplessness, 1
 - locomotor activity, 515
 - model of depression, 805
 - pharmacological analysis, 515
 - ³H-prazosin, 329
 - REM sleep deprivation, 329
 - serotonergic neurons, 1
 - serotonergic receptors, 805
- Antinociception
 - age differences, 599
 - anesthesia, 641
 - cardiovascular system, 641
 - drug comparisons, 835
 - drug interactions, 835
 - locomotor activity, 599
 - [D-Ala²]-methionine enkephalinamide (DALA), 641
 - morphine, 599, 835
 - renal sympathetic nerve, 641
 - tizanidine, 835
 - tolerance, 835
- Antinociceptive system, 533
 - morphine
 - opiate tolerance
 - stimulation-produced analgesia
- Antipsychotic drugs, 897
 - acute administration
 - chronic administration
 - spontaneous chewing movements
 - tardive dyskinesia
- Anxiety
 - anxiolytic drugs, 371
 - beta-blockers, 371
 - convulsions, 595
 - 6,7-dimethoxy, 4 ethyl β-carboline
 - carboxylic acid methyl ester, 595
 - locomotor activity, 595
- naltrexone, 595
- pigeons, 371
- propunishment, 595
- punished responding, 371
- Anxiolytic drugs, 371
 - anxiety
 - beta-blockers
 - pigeons
 - punished responding
- Apomorphine
 - behavioral deficits, 503
 - cognitive deficits, 503
 - dopamine receptors, 473
 - dopaminergic mechanism, 693
 - exploratory behavior, 473
 - lateralized rotation, 689
 - neuroleptics, 473, 503
 - operant behavior, 503
 - postural asymmetry, 689
 - shock escape mechanisms, 693
- Apomorphine-induced stereotypy, 757
 - dopaminergic neuron activity
 - MSH-release inhibiting factor-1 (MIF-1)
 - Tyr-MSH-release inhibiting factor-1 (Tyr-MIF-1)
- Apparatus
 - Animex activity meter, 411
 - 8-choice arena, 747
 - holeboard, 473
 - intracerebral cannula system, 487
 - osmotic minipump, 1263
 - radial arm maze, 521, 703, 747, 1117
 - radiant heat apparatus, 481
 - rotometer, 1021
 - runway, 123
 - shuttlebox, 145
 - toggle-box, 289
 - Y catheter, 483
 - Y-maze, 29, 939
- Appetite regulation, 381
 - deprivation
 - eating
 - glucoprivic feeding
 - lesions, paraventricular nucleus (PVN)
- Appetite suppressants, 733
 - brown adipose tissue (BAT)
 - purine nucleotide binding
- Appetitive learning, 651
 - brain DNA
 - DNA synthesis
 - reverse handedness
- Area postrema, 269
 - conditioned taste aversion
 - locomotor activity
 - scopolamine
- N-methyl Aspartate, 943
 - acetylcholine release
 - drug interactions
 - locomotor activity
- Aspartic acid, 953
 - angiotensin converting enzyme (ACE) activity
 - brain asparaginase
 - morphine dependent rats
 - naloxone
 - plasma cortisol level
- Ca²⁺-ATPase activity, 549
 - dihydropyridine receptors
 - thermoregulation
- Atropine, 985
 - clonidine

- drug interactions
- locomotor activity
- stereotypy
- Autoradiography, 1051
 - discriminative stimulus properties
 - ³H-PCP binding potency
 - phencyclidine (PCP)-related compounds
- Avoidance conditioning, 673
 - age differences
 - maze learning
 - memory
 - scopolamine
- Avoidance learning, 469
 - inhibitory avoidance
 - substance P

- Barrel rotation
 - behavioral changes, 589
 - lesions, kainic acid, 583, 589
 - nicotine, 583
 - prostration, 583
 - receptors changes, 589
 - vasopressin, 583
 - vestibular cerebellum, 583
- Bat/rat/mouse/hamster comparisons, 527
 - brain opioid receptors
 - hibernation
- Behavioral analysis, 577
 - caloric intake
 - eating
 - human studies, males
 - marijuana
- Behavioral changes, 589
 - barrel rotation
 - lesions, kainic acid
 - receptor changes
- Behavioral deficits, 503
 - apomorphine
 - cognitive deficits
 - neuroleptics
 - operant behavior
- Behavioral despair test, 511
 - H₂-receptor blockers
 - naloxone
- Behavioral development, 1089
 - lead retention
 - preweaning lead exposure
- Benzodiazepine antagonists, 537
 - drug interactions
 - schedule-controlled behavior
- Benzodiazepine receptors, 215
 - analgesia
 - morphine
- Benzodiazepines
 - brown adipose tissue (BAT), 913
 - cafeteria diet, 913
 - chickens, 1237
 - chlordiazepoxide, 1237
 - conditioned taste aversion, 431
 - convulsions, 1145
 - drinking, 431
 - food intake, 913
 - food preference, 913
 - hyperactivity, 1145
 - neonates, 1145
 - polydipsia, 431
 - tolerance, 1237
 - tonic immobility, 1237
 - two-bottle choice paradigm, 431
 - type 2 receptors, 1145
- Beta-blockers, 371
 - anxiety
 - anxiolytic drugs
 - pigeons
 - punished responding
- Bicuculline, 1059
 - anticonvulsant effects
 - drug interactions
 - GABA_A receptors
 - maximal electroshock
 - pentobarbital
 - phenobarbital
 - picROTOXIN
 - seizures
- Bin analysis, 145
 - d-amphetamine
 - inter-response time
 - monkeys
 - Sidman avoidance schedule
- Blood pressure, 423
 - chemical stimulation
 - heart rate
 - mediodorsal nucleus of the thalamus
 - rabbits
- Body temperature, 1293
 - diisopropylfluorophosphate (DFP)
 - heart rate
 - locomotor activity
 - muscarinic receptors
 - ³H-quinuclidinyl benzilate (³H-QNB) binding
 - respiration rate
 - tolerance
- Body weight, 1131
 - caloric intake
 - nicotine
 - physical activity
 - rats, females
- Bombesin, 7
 - cholecystokinin (CCK)
 - dietary self-selection
 - isocaloric diets
- Brain
 - amygdala, 17, 95
 - anterior hypothalamus, 353
 - anteromedial caudate nucleus, 17
 - basal ganglia, 233
 - brainstem, 1253
 - caudal medulla, 347
 - caudate nucleus, 63, 521
 - cerebellum, 555
 - cerebral cortex, 1, 527, 743, 763, 903
 - cochlear nucleus, 347, 353
 - corpus striatum, 943
 - cortex, 329, 521, 555, 1293
 - dorsal hippocampus, 717
 - dorsal raphe nucleus, 717, 1211
 - entorhinal cortex, 651
 - fourth ventricle, 843
 - globus pallidus, 233
 - hippocampus, 1, 347, 423, 521, 651, 743, 781, 797, 1137, 1293
 - hypothalamus, 95, 381, 411, 527, 549, 555
 - lateral habenula nuclei, 717
 - lateral hypothalamus (LH), 59, 629
 - lateral ventricle, 411
 - locus coeruleus, 1211
 - magnocellular basal forebrain, 293
 - medial forebrain bundle, 629
 - medial frontal cortex, 17
 - medial hypothalamus, 401, 1223
 - medial prefrontal cortex, 191
 - medial septum, 521
 - median raphe nucleus, 717, 1211
 - midbrain central grey, 857
 - midbrain raphe, 1
 - midmesencephalon, 347
 - nodular cerebellum, 583, 589
 - nucleus accumbens, 17, 63, 263, 943, 1095, 1149
 - nucleus accumbens septi, 1027
 - nucleus basalis magnocellularis, 521
 - olfactory tubercle, 63
 - paramedian brainstem, 347
 - paraventricular nucleus (PVN), 381, 1223
 - pituitary, 967
 - pontine reticular formation (PRF), 1253
 - prefrontal cortex, 717
 - preoptic region, 353
 - right frontoparietal cortex, 263
 - septum, 95, 797
 - somatosensory cortex, 607
 - striatum, 1, 297, 763, 865, 1027, 1095, 1293
 - substantia nigra, 317, 1307
 - thalamus, 423
 - ventral striatum, 233
 - ventral tegmental area, 959
 - ventrolateral caudate nucleus, 17
 - ventromedial hypothalamus (VMH), 59
 - vestibular cerebellum, 583
 - visual cortex, 651
- Brain asparaginase, 953
 - angiotensin converting enzyme (ACE) activity
 - aspartic acid
 - morphine dependent rats
 - naloxone
 - plasma cortisol level
- Brain catecholamines, 1027
 - amphetamine self-administration
 - L-tyrosine
- Brain DNA, 651
 - appetitive learning
 - DNA synthesis
 - reverse handedness
- Brain iron-deficiency, 141
 - learning
 - water maze
- Brain monoamines, 401
 - hyperphagia
 - lesions, medial hypothalamus
 - obesity
- Brain noradrenergic system, 411
 - l-erythro-dihydroxyphenylserine (L-erythro-DOPS)
 - locomotor activity
- Brain opioid receptors, 527
 - bat/rat/mouse/hamster comparisons
 - hibernation
- Brain stimulation, 629
 - drug interactions
 - nalbuphine
 - reward threshold
 - tripilennamine
- Brown adipose tissue (BAT)
 - appetite suppressants, 733
 - benzodiazepines, 913
 - cafeteria diet, 913
 - food intake, 913
 - food preference, 913
 - purine nucleotide binding, 733

- Buccal mucosa, 1181
 - human studies
 - nicotine absorption
 - passive smoking
- Bull breeds, 71
 - aggression
 - limbic system
 - neurotransmitter amino acids
- Buspirone, 457
 - corticosterone secretion
 - prolactin secretion
 - stress
- BW813U, 521
 - choline acetyltransferase (ChAT)
 - inhibitor
 - radial maze performance
 - spatial memory
- Cafeteria diet, 913
 - benzodiazepines
 - brown adipose tissue (BAT)
 - food intake
 - food preference
- Caffeine, 1271
 - locomotor activity
 - strain differences
 - theophylline
- Calcium antagonist binding, 51
 - acylating phencyclidines
 - drug interactions
- Calcium antagonists, 45
 - drug interactions
 - motor activity
 - phencyclidine (PCP)
- Calcium channel antagonists, 555
 - drug interactions
 - hyperthermia
 - thermoregulation
- Caloric intake
 - behavioral analysis, 577
 - body weight, 1131
 - eating, 577
 - human studies, males, 577
 - marijuana, 577
 - nicotine, 1131
 - physical activity, 1131
 - rats, females, 1131
- Cannabidiol, 89
 - cats
 - electrophysiological properties
 - spinal motoneurons
 - synaptic effects
- Carbon monoxide exposure, 1245
 - filter vent blocking
 - human studies
 - smoking topography
 - tobacco
- Cardiovascular system, 641
 - anesthesia
 - antinociception
 - [D-Ala²]-methionine enkephalinamide
 - renal sympathetic nerve
- Cataleptic behavior, 463
 - drug interactions
 - neuroleptics
 - prostaglandins
- Catecholamines, 949
 - α -methyl-p-tyrosine
 - 6-hydroxydopamine (6-OHDA)
 - seizures, pentylentetrazol (PTZ)
 - induced
- l-Cathinone
 - chronic administration, 13
 - dopaminergic neuronal systems, 337
 - drug discrimination, 13, 337
 - drug interactions, 337
 - tolerance, 13
- Cats
 - age differences, 359
 - cannabidiol, 89
 - electrophysiological properties, 89
 - phencyclidine (PCP) metabolites, 359
 - spinal motoneurons, 89
 - synaptic effects, 89
 - tolerance, 359
- Cerebral cortex, 903
 - alpha adrenoceptors
 - cold exposure
- CGS 8216
 - drinking, 341
 - drug interactions, 439
 - ethanol, 439
 - naltrexone, 439
 - saccharin consumption, 341
 - shock avoidance, 439
 - timeout from avoidance, 439
- Chemical stimulation, 423
 - blood pressure
 - heart rate
 - mediodorsal nucleus of the thalamus
- Chickens, 1237
 - benzodiazepines
 - chlordiazepoxide
 - tolerance
 - tonic immobility
- Chicks, 823
 - memory
 - testosterone
- Chlordiazepoxide
 - benzodiazepines, 1237
 - chickens, 1237
 - sodium valproate, 747
 - spatial behavior, 747
 - tolerance, 1237
 - tonic immobility, 1237
- Chlordiazepoxide-induced sleep, 1077
 - GABAergic drugs
 - selective breeding
- N-(2-Chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4), 743
 - α_1 -adrenoceptors
 - β -adrenoceptors
 - functional sensitivity
 - noradrenergic denervation
- Cholecystokinin (CCK)
 - bombesin, 7
 - dietary self-selection, 7
 - hamsters, 1067
 - hyperactivity, 1067
 - hypoactivity, 1067
 - isocaloric diets, 7
 - morphine, 1067
- Cholesterol, 1285
 - dietary manipulation
 - essential fatty acids
 - ethanol preference
 - hamsters
 - retinal palmitate
- Choline acetyltransferase (ChAT)
 - inhibitor, 521
 - BW813U
 - radial maze performance
 - spatial memory
- Cholinesterase inhibition, 1071
 - clinical chemistry
 - heat
 - pyridostigmine
 - thermoregulation
- Cholinesterase inhibitors, 1217
 - perioral behaviors
 - physostigmine
 - tardive dyskinesia
- Cholinomimetics, 1253
 - chronic microinfusion
 - rapid eye movement (REM) sleep
- Chronic administration
 - acute administration, 897, 1195
 - aggression, 1195
 - ambient temperature, 667
 - antipsychotic drugs, 897, 1195
 - l-cathinone, 13
 - dopamine receptors, 129
 - drug discrimination, 13
 - ethanol, 667
 - hypothermia, ethanol-induced, 667
 - magnesium, 1195
 - motor activity, 129
 - phenylethylamine, 129
 - sensitization, 129
 - spontaneous chewing movements, 897
 - tardive dyskinesia, 897
 - tolerance, 13, 667, 1195
- Chronic infusion, 483
 - intrathecal injection
 - tolerance
- Chronic microinfusion, 1253
 - cholinomimetics
 - rapid eye movement (REM) sleep
- Circadian rhythm, 333
 - sedation hypnosis
 - sleep time
 - strain differences
- Circling behavior, 1021
 - locomotor activity
 - prenatal alcohol exposure
- Circling, opiate-induced, 959
 - dopaminergic system
 - opiate receptors
 - ventral tegmental area
- Classical conditioning
 - analgesia, 1201
 - cross tolerance, 35
 - drug reinforcement, 1169
 - environmental specific cues, 1201
 - ethanol, 35
 - exploratory behavior, 1169
 - habituation, 1169, 1201
 - morphine, 1169, 1201
 - place preference, 1169
 - snails, 1201
 - sodium pentobarbital, 35
 - stress, 1201
 - stress-induced analgesia, 181
 - tail flick, 181
 - tolerance, 1201
- Clinical chemistry, 1071
 - cholinesterase inhibition
 - heat
 - pyridostigmine
 - thermoregulation
- Clonidine
 - adrenergic receptors, 989
 - atropine, 985
 - continuous infusion, 989
 - drug interactions, 985, 989

- eating, 1107
- hamsters, 1107
- locomotor activity, 985
- naloxone, 989
- opiate abstinence syndrome, 989
- stereotypy, 985
- Cocaine
 - acoustic startle, 1175
 - amphetamine, 1175
 - cross-tolerance, 1175
 - habituation, 1175
 - haloperidol, 497
 - lesions, neurotoxic, 191
 - medial prefrontal cortex, 191
 - phencyclidine (PCP), 1175
 - presynaptic dopaminergic terminal, 191
 - self-administration, 497
 - self-administration, intracranial, 191
 - sensitization, 1175
 - sex differences, 497
 - tamoxifen, 497
 - tolerance, 1175
- Cochlear nucleus (CN), 353
 - prostaglandin (PGE₁), pyrexia
- Cognitive deficits, 503
 - apomorphine
 - behavioral deficits
 - neuroleptics
 - operant behavior
- Cold exposure, 903
 - alpha adrenoceptors
 - cerebral cortex
- Cold-restraint stress, 775
 - gastric ulceration
 - motility
- Cold water swim, 171
 - analgesia, stress-induced
 - hyperphagia
 - hypothermia
 - muscarinic agents
 - pain
- Conditioned aversions, 973
 - drug-paired stimuli
 - lever pressing
 - lithium chloride (LiCl)
 - monkeys
- Conditioned hyperactivity hypothesis, 83
 - drug interactions
 - thermic response shifts
- Conditioned place aversion, 1041
 - conditioned place preference
 - locomotor activity
 - nicotine
- Conditioned place preference
 - conditioned place aversion, 1041
 - drug reinforcement, 1101
 - locomotor activity, 1041
 - morphine, 1101
 - nicotine, 1041
 - single-trial, 1101
- Conditioned taste aversion
 - area postrema, 269
 - benzodiazepines, 431
 - drinking, 431
 - duration of action, 995
 - locomotor activity, 269
 - polydipsia, 431
 - scopolamine, 269
 - temporal analysis, 995
 - tryptamine, 995
 - two-bottle choice paradigm, 431
- Consolidation, 1125
 - memory effects, time related
 - passive avoidance behavior
 - retrieval
 - vasopressin
 - vasopressin analogues
- Continuous infusion, 989
 - adrenergic receptors
 - clonidine
 - drug interactions
 - naloxone
 - opiate abstinence syndrome
- Convulsions
 - anxiety, 595
 - benzodiazepines, 1145
 - 6,7-dimethyl, 4 ethyl β -carboline carboxylic acid methyl ester, 595
 - hyperactivity, 1145
 - locomotor activity, 595
 - naltrexone, 595
 - neonates, 1145
 - propunishment, 595
 - type 2 receptors, 1145
- Corticosterone, 107
 - oxytocin
 - psychological stressor
- Corticosterone secretion, 457
 - bupirone
 - prolactin secretion
 - stress
- Corticosterone synthesis, 753
 - adrenal cortex
 - adrenocorticotrophin 1–24 (ACTH 1–24)
 - steroidogenesis
- Cross tolerance
 - acoustic startle, 1175
 - amphetamine, 1175
 - classical conditioning, 35
 - cocaine, 1175
 - ethanol, 35
 - habituation, 1175
 - phencyclidine (PCP), 1175
 - sensitization, 1175
 - sodium pentobarbital, 35
 - tolerance, 1175
- ³H-Cyclic AMP, 223
 - adenylate cyclase
 - norepinephrine (NE)
 - REM sleep deprivation
- Cyclo (leucyl-glycyl) (cLG), 1279
 - dopamine receptors
 - haloperidol
 - stereotypy, apomorphine-induced
 - supersensitivity
- Cycloheximide, 567
 - amnesia
 - anisomycin
 - drug interactions
 - naloxone
 - passive avoidance
 - shuttle avoidance
- Cytisine, 843
 - dogs
 - fourth ventricle
 - high/low affinity sites
 - 2-methylpiperidine
 - nicotine
- D₂ receptors, 1185
 - dopamine
 - internal clock speed
 - neuroleptics
 - time estimation
- Deer mouse, 543
 - food hoarding
 - ingestion
 - opiate agonists
- Defensive behavior, 561
 - diazepam
 - environmental constraints
 - fear reactions
- Delayed-matching-to-sample, 929
 - drug interactions
 - phenobarbital
 - phenytoin
 - pigeons
 - valproic acid
- Delayed performance, 201
 - monkeys
 - phencyclidine (PCP)
 - repeated acquisition
 - response chains
 - retention
- Delayed response, 633
 - discrimination
 - response bias
 - scopolamine
 - working memory
- 2-Deoxy-D-glucose
 - feeding behavior, 59
 - glucoprivation, 1153
 - hyperphagia, 59
 - hypophagia, 1153
 - lateral hypothalamus, 59
 - liquid diet, 1153
 - 5-thiogluucose, 59
 - ventromedial hypothalamus, 59
 - water deprivation, 1153
- Deprivation
 - appetite regulation, 381
 - eating, 381, 1223
 - glucoprivic feeding, 381
 - lesions, paraventricular nucleus (PVN), 381
 - medial hypothalamus, 1223
 - norepinephrine (NE), 1223
 - paraventricular nucleus (PVN), 1223
 - serotonin, 1223
- Diazepam, 561
 - defensive behavior
 - environmental constraints
 - fear reactions
- Dietary manipulation, 1285
 - cholesterol
 - essential fatty acids
 - ethanol preference
 - hamsters
 - retinol palmitate
- Dietary self-selection, 7
 - bombesin
 - cholecystokinin (CCK)
 - isocaloric diets
- Dietary starch, 491
 - acarbose
 - intestinal distention
- Differential reinforcement of low rate of response (DRL), 1191
 - fixed ratio performance
 - operant behavior
 - 3-quinuclidinyl benzilate (QNB)
 - schedule dependent effects
- ³H-Dihydroalprenolol binding, 329
 - adrenoceptors

- antidepressants
- ³H-prazosin
- REM sleep deprivation
- Dihydropyridine receptors, 549
 - Ca⁺-ATPase activity
 - thermoregulation
- Diisopropylfluorophosphate (DFP), 1293
 - body temperature
 - heart rate
 - locomotor activity
 - muscarinic receptors
 - ³H-quinuclidinyl benzilate (³H-QNB) binding
 - respiration rate
 - tolerance
- 6,7-Dimethy, 4 ethyl β -carboline
- carboxylic acid methyl ester (DMCM), 595
 - anxiety
 - convulsions
 - locomotor activity
 - naltrexone
 - propunishment
- Diphenhydramine, 365
 - driving related tasks
 - human studies, males
 - plasma levels
- Discrimination, 633
 - delayed response
 - response bias
 - scopolamine
 - working memory
- Discriminative stimulus properties, 1051
 - autoradiography
 - ³H-PCP binding potency
 - phencyclidine (PCP)-related compounds
- Diurnal cycle, 293
 - lesions, nucleus basalis magnocellularis
 - locomotor activity
- DNA synthesis, 651
 - appetitive learning
 - brain DNA
 - reverse handedness
- Dogs, 843
 - cytisine
 - fourth ventricle
 - high/low affinity sites
 - 2-methylpiperidine
 - nicotine
- DOPAC concentrations, 63
 - electrical stimulation
 - intracranial self-stimulation
 - in vivo
 - nigro-striatal pathway
- DOPAC/DA ratio, 865
 - dopamine release
 - striatal dopamine system
 - unilateral barpressing
- Dopamine, 1185
 - D₂ receptors
 - internal clock speed
 - neuroleptics
 - time estimation
- Dopamine agonists, 249
 - dopamine antagonists
 - locomotor activity
- Dopamine antagonists, 249
 - dopamine agonists
 - locomotor activity
- Dopamine autoreceptor agonists, 255
 - exploratory activity
 - locomotor activity, drug-induced
- Dopamine depletion, 1307
 - amphetamine
 - lesions, 6-hydroxydopamine (6-OHDA)
 - lesions, substantia nigra
 - recovery
 - rotation
- Dopamine metabolism, 1095
 - feeding behavior
 - ingestion
 - nucleus accumbens
 - striatum
- Dopamine receptors
 - adrenergic receptors, 763
 - apomorphine, 473
 - chronic administration, 129
 - cyclo (leucyl-glycyl) (cLG), 1279
 - exploratory behavior, 473
 - haloperidol, 1279
 - marijuana, 763
 - motor activity, 129
 - neuroleptics, 473
 - perinatal exposure, 763
 - phenylethylamine (PEA), 129
 - sensitization, 129
 - stereotypy, apomorphine-induced, 1279
 - supersensitivity, 1279
 - tyrosine hydroxylase activity, 763
- Dopamine release, 865
 - DOPAC/DA ratio
 - striatal dopamine system
 - unilateral barpressing
- Dopamine systems, 1117
 - LY 171555
 - radial arm maze
- Dopamine terminal area, 17
 - adipsia
 - amphetamine
 - anorexia
- Dopaminergic mechanisms, 693
 - apomorphine
 - shock escape learning
- Dopaminergic neuron activity, 757
 - apomorphine-induced stereotypy
 - MSH-release inhibiting factor-1 (MIF-1)
 - Tyr-MSH-release inhibiting factor-1 (Tyr-MIF-1)
- Dopaminergic neuronal systems, 337
 - l-cathinone
 - drug discrimination
 - drug interactions
- Dopaminergic system, 959
 - circling, opiate-induced
 - opiate receptors
 - ventral tegmental area
- Dose-dependent effects, 1207
 - drug discrimination
 - 5-methoxy-N,N-dimethyltryptamine (5-OMe DMT)
 - serotonin antagonists
 - stimulus properties
- Drinking
 - adjunctive consumption, 1159, 1163
 - alcohol, 1159, 1163
 - benzodiazepines, 431
 - CGS 8216, 341
 - conditioned taste aversion, 431
 - extinction, 1159, 1163
 - hamsters, 449
 - high-caloric fluids, 449
 - lithium, 1159, 1163
 - morphine, 1001
 - naloxone, 697
 - naloxone-precipitated withdrawal, 1001
 - opioid agonists, 77
 - palatability, 697
 - physical dependence, 1001
 - polydipsia, 431
 - reproduction, 449
 - saccharin consumption, 341
 - satiation, 697
 - sequential presentation, 697
 - shock, 1163
 - social stress, 449
 - stress, 1163
 - sucrose, 1001
 - two-bottle choice paradigm, 431
 - water, 1159
 - water balance, 77
- Driving related tasks, 365
 - diphenhydramine
 - human studies, males
 - plasma levels
- Drug
 - alcohol, 1159, 1163
 - amino-oxyacetic acid, 1077
 - aminophosphonovaleric acid, 943
 - amisulpride, 503
 - ammonium sulfate, 161
 - amphetamine, 17, 129, 155, 161, 277, 515, 711, 919, 1149, 1175, 1307
 - d-amphetamine, 29, 123, 145, 255, 297, 733, 849, 939, 1021, 1027
 - anisomycin, 567
 - apomorphine, 41, 255, 277, 473, 503, 689, 757, 1279
 - apomorphine hydrochloride, 693
 - artificial cerebrospinal fluid (5-ion), 411
 - l-aspartic acid, 953
 - aspirin, 463
 - atenolol, 371
 - atropine, 775, 897, 985
 - atropine sulfate, 83
 - baclofen, 1059
 - BAY K8644, 549, 555
 - bethanechol, 775
 - bicuculline, 59, 1059, 1077
 - brotizolam, 913
 - buspirone, 457
 - BW813U, 521
 - caffeine, 277
 - cannabidiol, 89
 - cannabinol monoethyl ether, 393
 - captopril, 317
 - carbachol, 423, 1253
 - l-cathinone, 13, 337
 - CGS 8216, 341, 439, 537
 - chlordiazepoxide, 431, 747, 973, 1077, 1237
 - N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4), 743
 - p-chlorophenylalanine (PCPA), 415
 - chlorpromazine, 255, 503, 805, 897, 1185
 - choline, 925
 - cimetidine, 511
 - cinanserin, 1207, 1223
 - cis-flupenthixol, 473
 - CL 218,872, 1145
 - clomipramine, 1, 515, 805
 - clonazepam, 1145

- clonidine, 835, 985, 989, 1107, 1211
 clozapine, 255, 897
 cocaine, 191, 497, 1175
 cycloheximide, 567
 N⁶cyclohexyladenosine, 1271
 cyproheptadine, 1207
 cytisine, 843
 2-deoxy-D-galactose, 1137
 2-deoxy-D-glucose, 59, 171, 1153
 desipramine, 1, 805
 dexamethasone, 781
 dextrorphan tartrate, 959
 diazepam, 215, 431, 537, 561, 913, 1145
 N-N-dichethylaminophenylhexyl-
 amine, 359
 diethylpropion, 733
 dihydropyridine, 51
 5,7-dihydroxytryptamine, 1
 diisopropylfluorophosphate (DFP),
 1293
 diltiazem, 51, 549, 555
 6,7-dimethoxy, 4 ethyl β -carboline
 carboxylic acid methyl ester
 (DMCM), 595
 1-(2,5-dimethoxy-4-methylphenyl)-2-
 aminopropane (DOM), 135
 4-(5,6-dimethyl-2-benzofuranyl/
 piperidine hydrochloride
 (CGP 6085 A), 743
 diprenorphine HCl, 959
 dopamine, 191, 813, 943, 1185
 doxepine, 805
 EMD 23448, 255
 L-erythro-dihydroxyphenylserine
 (L-erythro-DOPS), 411
 ethanol, 35, 289, 333, 439, 607, 667,
 889, 1013, 1021, 1035, 1083, 1285
 5'-(N-ethylcarboxamide) adenosine,
 769, 1271
 ethylketazocine methanesulfonate, 959
 ethylketocyclazocine, 77
 etiracetam, 925
 fenfluramine, 123, 733, 967, 1223
 FG 7142, 99
 fluoxetine, 515
 fluphenazine, 503, 897
 FOURPHIT, 51
 l-glutamate, 423
 haloperidol, 255, 337, 463, 473, 497,
 503, 791, 813, 897, 959, 1175, 1185,
 1231, 1279
 harmine, 111
 hemicholinium-3, 925
 hydralazine, 317
 p-hydroxyamphetamine, 161
 6-hydroxydopamine (6-OHDA), 191,
 381, 401, 949
 8-hydroxy-2-(di-n-propylamino)
 tetralin (8-OH DPAT), 135
 N-(5-hydroxypentyl)-1-phenylcyclo-
 hexylamine, 359
 5-hydroxytryptamine (5-HT), 23, 849,
 883
 5-hydroxy-L-tryptophan (5-HTP), 805,
 873
 idazoxan, 903
 imipramine, 1, 149, 805
 indomethacin, 739
 iprazid, 515
 kainic acid, 297, 589
 ketamine, 111
 ketanserin, 135
 ketocyclazocine hydrochloride, 543
 lead, 1089
 levorphanol bitartrate, 959
 lithium chloride (LiCl), 431, 973, 1159,
 1163
 lorazepam, 1145
 LY 171555, 1117
 lysergic acid diethylamide (LSD), 41,
 227, 717
 magnesium, 1195
 marijuana, 577, 763
 mazindol, 733
 METAPHIT, 51
 metazocine, 785
 metergoline, 1223
 methadone, 149, 959
 d-methamphetamine, 1035
 methanesulfonyl fluoride, 1217
 methergoline, 1207
 [D-Ala²]-methionine enkephalinamide
 (DALA), 641
 5-methoxy-N,N-dimethyltrypta-
 mine (5-OMe DMT), 1207
 N-methyl aspartate (NMA), 943
 2-methylpiperidine, 843
 methylscopolamine, 171, 633, 673
 [³H-methyl]thymidine, 651
 α -methyl-p-tyrosine (α -MPT), 949
 methysergide, 23, 805, 1207, 1223
 metoclopramide, 473, 503
 mianserin, 805
 midazolam, 99
 morphine, 77, 209, 215, 481, 533, 555,
 599, 835, 1001, 1007, 1067, 1101,
 1169, 1201, 1263
 morphine sulphate, 959
 muscimol, 1059
 nalbuphine, 629
 naloxone, 123, 209, 511, 533, 543, 567,
 697, 835, 953, 989, 1007, 1101, 1263
 naloxone hydrochloride, 555, 959
 naltrexone, 123, 439, 575, 595, 959
 nialamide, 1, 943
 nicotine, 185, 277, 583, 589, 727, 843,
 879, 1131
 nifedipine, 45
 nimodipine, 549, 555
 nitrendipine, 51
 norepinephrine (NE), 223, 381
 8-OH-2-(di-n-propylamino)tetralin
 (8-OH-DPAT), 883
 oxotremorine, 1293
 oxytocin, 107
 pentetrazole, 41
 pentobarbital, 333, 375, 835, 1059
 pentylenetetrazol (PTZ), 949, 1077
 phenacyclidine (PCP), 45, 51, 117, 129,
 185, 201, 359, 785, 827, 1175
 phenacyclidine hydrochloride, 959
 phenobarbital, 929, 1059
 phentermine, 623
 1-phenylcyclohexylamine, 827
 1-(1-phenylcyclohexyl)-4-hydroxy-
 piperidine, 827
 (-)N⁶phenylisopropyladenosine, 1271
 1-(1-phenyl-4-hydroxycyclohexyl)
 piperidine, 827
 phenylephrine, 743
 phenylethylamine (PEA), 129, 711
 phenylmethanesulfonyl fluoride, 1217
 phenytoin, 929
 physostigmine, 1217
 picrotoxin, 59, 1059, 1077
 pilocarpine, 463
 pimoline, 933
 pimozone, 219, 503, 615, 711, 1185
 piperoxan, 155
 piracetam, 925
 pirenperone, 111
 pizotyline, 227
 pramiracetam, 925
 prazosin, 903
 procaine, 583, 857
 promazine, 1185
 propranolol, 23, 41, 135, 371, 463
 N-n-propyl-3-(3-hydroxyphenyl)-
 piperidine (3-PPP), 255
 N-n-propylnorapomorphine (NPA),
 255
 pyrazidol, 515
 pyridostigmine, 1071
 3-quinuclidinyl benzilate (QNB), 1191
 racemic N-allyl-N-normetazocine
 (SKF 10,047), 959
 ranitidine, 511
 rauwolscine, 155
 Ro 15-1788, 215, 537, 1145
 RS 21361, 155
 RX-781094, 155, 903
 SCH 23390, 473
 scopolamine, 171, 277, 673, 1253
 scopolamine hydrochloride, 269
 scopolamine methyl nitrate, 269
 secobarbital, 375
 serotonin, 191, 1223
 SKF 83566, 249
 sodium pentobarbital, 35, 83
 sodium valproate (VPA), 747
 spiperone, 135
 spiroperidol, 1185
 sulphiride, 191, 473, 503, 897
 tamoxifen, 497
 Δ^1 -tetrahydrocannabinol (Δ^1 -THC),
 393
 Δ^9 -tetrahydrocannabinol (Δ^9 -THC),
 827
 tetrodotoxin, 857
 theobromine, 769
 5-thioglucose, 59
 thioridazine, 503, 897
 tizanidine, 835
 tolazoline, 155
 trazodone, 515, 805
 1-(3-trifluoromethylphenyl)piperazine
 (TFMPP), 135
 tripeleminamine, 629
 tryptamine, 995
 L-tryptophan, 849
 L-tyrosine, 1027
 U50,488H, 77, 543
 valproic acid, 929
 verapamil, 45, 227, 549, 555, 775
 yohimbine, 155
 zimelidine, 805
 zolpidem, 537
 Drug comparisons
 antinociception, 835
 drug interactions, 835, 1035
 ethanol, 1035
 inhibition and stimulation, 1035
 locomotor activity, 1035
 d-methamphetamine, 1035
 morphine, 835

- tizanidine, 835
- tolerance, 835
- Drug discrimination
 - l-cathinone, 13, 337
 - chronic administration, 13
 - dopaminergic neuronal systems, 337
 - dose-dependent effects, 1207
 - drug interactions, 337
 - hexahydrocannabinol stereochemistry, 393
 - 8-hydroxy-2-(di-n-propyl-amino)tetralin (8-OH DPAT), 135
 - ketanserin pretreatment, 135
 - metazocine, 785
 - 5-methoxy-N,N-dimethyltryptamine (5-OMe DMT), 1207
 - monkeys, 785
 - morphine, 209
 - naloxone antagonism, 209
 - phencyclidine (PCP), 117
 - pigeons, 117, 209
 - plasma phencyclidine, 117
 - rat/pigeon comparisons, 393
 - self-administration, 785
 - serotonin antagonists, 1207
 - stimulus properties, 785, 1207
 - tetralin analogues, 135
 - tolerance, 13
- Drug interactions
 - acetylcholine release, 943
 - acylating phencyclidines, 51
 - adrenergic receptors, 989
 - amnesia, 567, 925
 - anisomycin, 567
 - anticonvulsant effects, 1059
 - antinociception, 835
 - atropine, 985
 - benzodiazepine antagonists, 537
 - bicuculline, 1059
 - brain stimulation, 629
 - calcium antagonist binding, 51
 - calcium antagonists, 45
 - calcium channel antagonists, 555
 - cataleptic behavior, 463
 - l-cathinone, 337
 - CGS 8216, 439
 - clonidine, 985, 989
 - conditioned hyperactivity hypothesis, 83
 - continuous infusion, 989
 - cycloheximide, 567
 - delayed-matching-to-sample, 929
 - dopaminergic neuronal systems, 337
 - drug comparisons, 835, 1035
 - drug discrimination, 337
 - endogenous opioids, 1007
 - ethanol, 439, 1035
 - GABA_A receptors, 1059
 - hemicholinium-3, 925
 - 5-hydroxytryptamine (5-HT), 23
 - hyperdipsia, 23
 - hyperthermia, 555
 - hypophagia, 23
 - imipramine, 149
 - inhibition and stimulation, 1035
 - locomotor activity, 943, 985, 1035
 - maximal electroshock, 1059
 - methadone, 149
 - d-methamphetamine, 1035
 - N-methyl aspartate (NMA), 943
 - methysergide, 23
 - monkeys, 185
 - morphine, 835
 - motor activity, 45
 - nalbuphine, 629
 - naloxone, 567, 989
 - naltrexone, 439
 - neuroleptics, 463
 - nicotine, 185
 - opiate abstinence syndrome, 989
 - opiates, 1007
 - passive avoidance, 567
 - pentobarbital, 1059
 - phencyclidine (PCP), 45, 185
 - phenobarbital, 929, 1059
 - phenytoin, 929
 - picrotoxin, 1059
 - pigeons, 149, 929
 - piracetam-like compounds, 925
 - postpartum aggression, 1007
 - propranolol, 23
 - prostaglandins, 463
 - repeated acquisition, 185
 - response chains, 185
 - reward threshold, 629
 - schedule-controlled behavior, 537
 - seizures, 1059
 - shock avoidance, 439
 - shuttle avoidance, 567
 - stereotypy, 985
 - thermic response shifts, 83
 - thermoregulation, 555
 - timeout from avoidance, 439
 - tizanidine, 835
 - tolerance, 835
 - tripelennamine, 629
 - valproic acid, 929
 - variable interval schedule, 149
- Drug-paired stimuli, 973
 - conditioned aversions
 - lever pressing
 - lithium chloride (LiCl)
 - monkeys
- Drug reinforcement
 - classical conditioning, 1169
 - conditioned place preference, 1101
 - exploratory behavior, 1169
 - habituation, 1169
 - morphine, 1101, 1169
 - place preference, 1169
 - single-trial, 1101
- Duration of action, 995
 - conditioned taste aversion
 - temporal analysis
 - tryptamine
- Duration of response, 615
 - anhedonia
 - force of response
 - pimozide
 - response rate
- Ear-withdrawal, 481
 - analgesimetry
 - rabbits
- Eating
 - amphetamine, 1149
 - anorexia, 99
 - appetite regulation, 381
 - behavioral analysis, 577
 - caloric intake, 577
 - clonidine, 1107
 - deprivation, 381, 1223
 - FG 7142, 99
 - glucoprivic feeding, 381
 - grooming, 99
 - hamsters, 1107
 - human studies, males, 577
 - hyperphagia, 99
 - lesions, paraventricular nucleus (PVN), 381
 - locomotor activity, 99, 1149
 - marijuana, 577
 - medial hypothalamus, 1223
 - midazolam, 99
 - norepinephrine (NE), 1223
 - nucleus accumbens, 1149
 - paraventricular nucleus (PVN), 1223
 - rearing, 99
 - serotonin, 1223
- Eating motivation, 123
 - amphetamine
 - fenfluramine
 - naloxone
 - naltrexone
 - satiety
- EEG alpha activity, 889
 - ethanol-induced euphoria
 - human studies, males
 - plasma ethanol levels
- Electrical stimulation, 63
 - DOPAC
 - intracranial self-stimulation
 - in vivo
 - nigro-striatal pathway
- Electroencephalographic effects, 879
 - human studies, smokers
 - nicotine gum
 - tobacco deprivation
- Electrophysiological properties, 89
 - cannabidiol
 - cats
 - spinal motoneurons
 - synaptic effects
- Endogenous opiates, 1303
 - opiate receptor sites
 - peptide interactions
 - Tyr-MSH-release inhibiting factor-1 (Tyr-MIF-1)
- Endogenous opioids
 - drug interactions, 1007
 - naltrexone, 573
 - opiates, 1007
 - postpartum aggression, 1007
 - prenatal stress, 573
 - sexual behavior differentiation, 573
- Environmental constraints, 561
 - defensive behavior
 - diazepam
 - fear reactions
- Environmental influences, 95
 - GABA receptors
 - muricide
- Environmental specific cues, 1201
 - analgesia
 - classical conditioning
 - habituation
 - morphine
 - snails
 - stress
 - tolerance
- L-Erythro-dihydroxyphenylserine (L-erythro-DOPS), 411
 - brain noradrenergic system
 - locomotor activity

- Escape deficit, 1
 - antidepressants
 - inescapable shocks
 - learned helplessness
 - serotonergic neurons
- Essential fatty acids, 1285
 - cholesterol
 - dietary manipulation
 - ethanol preference
 - hamsters
 - retinol palmitate
- Estrogen, 919
 - amphetamine-induced hyperactivity
 - time-dependent modulation
- Ethanol
 - ambient temperature, 667
 - CGS 8216, 439
 - chronic administration, 667
 - classical conditioning, 35
 - cross tolerance, 35
 - drug comparisons, 1035
 - drug interactions, 439, 1035
 - ethanol withdrawal, 1111
 - food-deprived/free-feeding rat
 - comparisons, 739
 - hypoglycemia, 739
 - hypothermia, 739
 - hypothermia, ethanol-induced, 667
 - indomethacin, 739
 - inhibition and stimulation, 1035
 - locomotor activity, 1035
 - d*-methamphetamine, 1035
 - naltrexone, 439
 - Pavlovian conditioning, 1111
 - radial arm maze performance, 703
 - sex differences, 703
 - shock avoidance, 439
 - sodium pentobarbital, 35
 - timeout from avoidance, 439
 - tolerance, 667
 - Ethanol effects, 607
 - single unit activity
 - somatosensory cortex
 - Ethanol-induced euphoria, 889
 - EEG alpha activity
 - human studies, males
 - plasma ethanol levels
 - Ethanol preference, 1285
 - cholesterol
 - dietary manipulation
 - essential fatty acids
 - hamsters
 - retinol palmitate
 - Ethanol tolerance, 797
 - limbic structures
 - serotonin synthesis
 - vasopressin-like peptides
 - Ethanol withdrawal, 1111
 - ethanol
 - Pavlovian conditioning
- Exploratory activity, 255
 - dopamine autoreceptor agonists
 - locomotor activity, drug-induced, 255
- Exploratory behavior
 - apomorphine, 473
 - classical conditioning, 1169
 - dopamine receptors, 473
 - drug reinforcement, 1169
 - habituation, 1169
 - morphine, 1169
 - neuroleptics, 473
 - place preference, 1169
- Exponential data analysis, 979
 - passive avoidance
 - step-through latencies
- Extinction
 - adjunctive consumption, 1159, 1163
 - alcohol, 1159, 1163
 - drinking, 1159, 1163
 - food reward, 813
 - haloperidol, 813
 - lithium, 1159, 1163
 - shock, 1163
 - stress, 1163
 - water, 1159
- Fear reactions, 561
 - defensive behavior
 - diazepam
 - environmental constraints
- Feeding behavior
 - 2-deoxy-D-glucose, 59
 - dopamine metabolism, 1095
 - hyperphagia, 59
 - ingestion, 1095
 - lateral hypothalamus, 59
 - nucleus accumbens, 1095
 - striatum, 1095
 - 5-thioglucoase, 59
 - ventromedial hypothalamus, 59
- Fenfluramine
 - amphetamine, 123
 - anorexia, 967
 - cating motivation, 123
 - gastrointestinal tract, 967
 - naloxone, 123
 - naltrexone, 123
 - opioid peptides, 967
 - satiety, 123
- FG 7142, 99
 - anorexia
 - cating
 - grooming
 - hyperphagia
 - locomotor activity
 - midazolam
 - rearing
- Filter vent blocking, 1245
 - carbon monoxide exposure
 - human studies
 - smoking topography
 - tobacco
- Finger tapping, 727
 - human studies, non-smokers
 - nicotine
- Fixed ratio/fixed interval schedule, 375
 - locomotor activity
 - pentobarbital
 - secobarbital
 - stereoisomers
 - variable interval schedule
- Fixed ratio performance, 1191
 - differential reinforcement of low rate of response (DRL)
 - operant behavior
 - 3-quinuclidinyl benzilate (QNB)
 - schedule dependent effects
- Focal brain injury, 263
 - lateralized hyperactivity
 - lesions, cortical island
- Food deprivation, 623
 - abrupt refeeding
 - phentermine
 - self-administration
- Food-deprived/free feeding rat
 - comparisons, 739
 - ethanol
 - hypoglycemia
 - hypothermia
 - indomethacin
 - Food hoarding, 543
 - deer mouse
 - ingestion
 - opiate agonists
 - Food intake, 913
 - benzodiazepines
 - brown adipose tissue (BAT)
 - cafeteria diet
 - food preference
 - Food preference, 913
 - benzodiazepines
 - brown adipose tissue (BAT)
 - cafeteria diet
 - food intake
 - Food reward, 813
 - extinction
 - haloperidol
 - Force of response, 615
 - anhedonia
 - duration of response
 - pimozide
 - response rate
 - Fourth ventricle, 843
 - cytisine
 - dogs
 - high/low affinity sites
 - 2-methylpiperidine
 - nicotine
 - Free-choice drinking, 1013
 - alcohol dehydrogenase
 - alcohol elimination rate
 - alcohol-preferring rats
 - metabolic tolerance
 - Functional sensitivity, 743
 - α_1 -adrenoceptors
 - β -adrenoceptors
 - N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4)
 - noradrenergic denervation
- GABA receptors, 95
 - environmental influences
 - muticide
- GABA_A receptors, 1059
 - anticonvulsant effects
 - bicuculline
 - drug interactions
 - maximal electroshock
 - pentobarbital
 - phenobarbital
 - picROTOXIN
 - seizures
- GABAergic drugs, 1077
 - chlordiazepoxide-induced sleep
 - selective breeding
- Gastric ulceration, 775
 - cold-restraint stress
 - motility
- Gastrointestinal tract, 967
 - anorexia
 - fenfluramine
 - opioid peptides
- Genetic behavior, 289
 - genetic breeding
 - habituation

- open-field activity
- pharmacogenetics
- Genetic breeding, 289
 - genetic behavior
 - habituation
 - open-field activity
 - pharmacogenetics
- Glucoprivation, 1153
 - 2-deoxy-D-glucose
 - hypophagia
 - liquid diet
 - water deprivation
- Glucoprivic feeding, 381
 - appetite regulation
 - deprivation
 - eating
 - lesions, paraventricular nucleus (PVN)
- Glycoprotein fucosylation, 1137
 - memory function
- Grooming, 99
 - anorexia
 - eating
 - FG 7142
 - hyperphagia
 - locomotor activity
 - midazolam
 - rearing

- H₂-receptor blockers, 511
 - behavioral despair test
 - naloxone
- Habituation
 - acoustic startle, 1175
 - amphetamine, 1175
 - analgesia, 1201
 - classical conditioning, 1169, 1201
 - cocaine, 1175
 - cross-tolerance, 1175
 - drug reinforcement, 1169
 - environmental specific cues, 1201
 - exploratory behavior, 1169
 - genetic behavior, 289
 - genetic breeding, 289
 - morphine, 1169, 1201
 - open-field activity, 289
 - pharmacogenetics, 289
 - phencyclidine (PCP), 1175
 - place preference, 1169
 - sensitization, 1175
 - snails, 1201
 - stress, 1201
 - tolerance, 1175, 1201
- Haloperidol
 - anhedonia, 1231
 - cocaine, 497
 - cycloleucyl-glycyl (cLGi), 1279
 - dopamine receptors, 1279
 - extinction, 813
 - food reward, 813
 - motor effects, 791
 - neuroleptics, 791
 - operant responding, 791
 - partial reinforcement extinction effect, 1231
 - reward omission, periodic, 1231
 - self-administration, 497
 - sex differences, 497
 - stereotypy, apomorphine-induced, 1279
 - supersensitivity, 1279
 - tamoxifen, 497
 - water reinforcement, 1231

- Hamsters
 - cholecystokinin (CCK), 1067
 - cholesterol, 1285
 - clonidine, 1107
 - dietary manipulation, 1285
 - drinking, 449
 - eating, 1107
 - essential fatty acids, 1285
 - ethanol preference, 1285
 - high-calorie fluids, 449
 - hyperactivity, 1067
 - hypoactivity, 1067
 - morphine, 1067
 - reproduction, 449
 - retinol palmitate, 1285
 - social stress, 449
- Harmine, 111
 - ketanserin
 - lordosis
 - pirenperone
- Heart rate
 - blood pressure, 423
 - body temperature, 1293
 - chemical stimulation, 423
 - diisopropylfluorophosphate (DFP), 1293
 - locomotor activity, 1293
 - mediodorsal nucleus of the thalamus, 423
 - muscarinic receptors, 1293
 - ³H-quinuclidinyl benzilate (³H-QNB) binding, 1293
 - rabbits, 423
 - respiration rate, 1293
 - tolerance, 1293
- Heat, 1071
 - cholinesterase inhibition
 - clinical chemistry
 - pyridostigmine
 - thermoregulation
- Hemicholinium-3, 925
 - amnesia
 - drug interactions
 - piracetam-like compounds
- Hexahydrocannabinol stereochemistry, 393
 - drug discrimination
 - rat/pigeon comparisons
- Hibernation, 527
 - bat/rat/mouse/hamster comparisons
 - brain opioid receptors
- High-calorie fluids, 449
 - drinking
 - hamsters
 - reproduction
 - social stress
- High/low affinity sites, 843
 - cytisine
 - dogs
 - fourth ventricle
 - 2-methylpiperidone
 - nicotine
- Hippocampal 5-HT activity, 781
 - rabbits
 - tonic immobility
- Hormone
 - estradiol, 857
 - estradiol benzoate, 111, 919
 - estrogen, 857
 - norepinephrine (NE), 1223
 - progesterone, 111, 857
 - prostaglandin, 463
 - prostaglandin (PGE₁), 347, 353
 - testosterone, 823
- Hotplate test, 933
 - pemoline
 - self-injurious behavior
 - stereotypy
- 5-HT syndrome, 873
 - offspring behavior
 - open-field behavior
 - prenatal stress
- Human studies
 - buccal mucosa, 1181
 - carbon monoxide exposure, 1245
 - filter vent blocking, 1245
 - marijuana smoking, 659
 - nicotine absorption, 1181
 - passive smoking, 1181
 - smoking topography, 1245
 - subjective ratings, 659
 - tobacco, 1245
 - tobacco smoking, 659
- Human studies, males
 - behavioral analysis, 577
 - caloric intake, 577
 - diphenhydramine, 365
 - driving related tasks, 365
 - eating, 577
 - EEG alpha activity, 889
 - ethanol-induced euphoria, 889
 - marijuana, 577
 - plasma ethanol levels, 889
 - plasma levels, 365
- Human studies, non-smokers, 727
 - finger tapping
 - nicotine
- Human studies, smokers, 879
 - electroencephalographic effects
 - nicotine gum
 - tobacco deprivation
- Huntington's disease, 297
 - animal model
 - locomotor hyperactivity
 - neural transplants
- 8-Hydroxy-2-(di-n-propylamino)tetrinalin (8-OH DPAT), 135
 - drug discrimination
 - ketanserin pretreatment
 - tetrinalin analogues
- 6-Hydroxydopamine (6-OHDA), 949
 - α -methyl-p-tyrosine (α -MPT)
 - catecholamines
 - seizures, pentylenetetrazol (PTZ) induced
- 5-Hydroxytryptamine (5-HT)
 - drug interactions, 23
 - hyperalgesia, 883
 - hyperdipsia, 23
 - hypoalgesia, 883
 - hypophagia, 23
 - methysergide, 23
 - nociception sensitivity, 883
 - 8-OH-2-(di-n-propylamino)tetrinalin (8-OH-DPAT), 883
 - propranolol, 23
 - route of administration, 883
- Hyperactivity
 - benzodiazepines, 1145
 - cholecystokinin (CCK), 1067
 - convulsions, 1145
 - hamsters, 1067
 - hypoactivity, 1067
 - morphine, 1067

- neonates, 1145
- type 2 receptors, 1145
- Hyperactivity drug induced, 711
 - amphetamine
 - anorexia, drug induced
 - phenylethylamine (PEA)
- Hyperalgesia, 883
 - 5-hydroxytryptamine (5-HT)
 - hypoalgesia
 - nociception sensitivity
 - 8-OH-2-(di-n-propylamino)tetralin (8-OH-DPAT)
 - route of administration
- Hyperdipsia, 23
 - drug interactions
 - 5-hydroxytryptamine (5-HT)
 - hypophagia
 - methysergide
 - propranolol
- Hyperphagia
 - analgesia, stress-induced, 171
 - anorexia, 99
 - brain monoamines, 401
 - cold water swim, 171
 - 2-deoxy-D-glucose, 59
 - eating, 99
 - feeding behavior, 59
 - FG 7142, 99
 - grooming, 99
 - hypothermia, 171
 - lateral hypothalamus, 59
 - lesions, medial hypothalamus, 401
 - locomotor activity, 99
 - midazolam, 99
 - muscarinic agents, 171
 - obesity, 401
 - pain, 171
 - rearing, 99
 - 5-thioglucose, 59
 - ventromedial hypothalamus, 59
- Hypertension, 317
 - lesions, substantia nigra
 - open field
 - strain differences
 - striatal dopamine content
- Hyperthermia, 555
 - calcium channel antagonists
 - drug interactions
 - thermoregulation
- Hypoactivity, 1067
 - cholecystokinin (CCK)
 - hamsters
 - hyperactivity
 - morphine
- Hypoalgesia, 883
 - 5-hydroxytryptamine (5-HT)
 - hyperalgesia
 - nociception sensitivity
 - 8-OH-2-(di-n-propylamino)tetralin (8-OH-DPAT)
- Hypocaloric diets, 681
 - insulin receptors
 - obesity
 - simple carbohydrate comparisons
- Hypoglycemia, 739
 - ethanol
 - food-deprived/free-feeding rat comparisons
 - hypothermia
 - indomethacin
- Hypophagia
 - 2-deoxy-D-glucose, 1153
- drug interactions, 23
- glucoprivation, 1153
- 5-hydroxytryptamine (5-HT), 23
- hyperdipsia, 23
- liquid diet, 1153
- methysergide, 23
- propranolol, 23
- water deprivation, 1153
- Hypothermia
 - adenosine receptors, 769
 - analgesia, stress-induced, 171
 - cold water swim, 171
 - ethanol, 739
 - food-deprived/free-feeding rat comparisons, 739
 - hyperphagia, 171
 - hypoglycemia, 739
 - inbred strains, 769
 - indomethacin, 739
 - locomotor activity, 769
 - methylxanthines, 769
 - muscarinic agents, 171
 - pain, 171
 - theobromine, 769
- Hypothermia, ethanol-induced, 667
 - ambient temperature
 - chronic administration
 - ethanol
 - tolerance
- Imipramine, 149
 - drug interactions
 - methadone
 - pigeons
 - variable interval schedule
- Immobilization, acute, 41
 - neurobiological responses
 - social isolation
- Inbred strains, 769
 - adenosine receptors
 - hypothermia
 - locomotor activity
 - methylxanthines
 - theobromine
- Indomethacin, 739
 - ethanol
 - food-deprived/free-feeding rat comparisons
 - hypoglycemia
 - hypothermia
- Inescapable shock, 1
 - antidepressants
 - escape deficit
 - learned helplessness
 - serotonergic neurons
- Ingestion
 - deer mouse, 543
 - dopamine metabolism, 1095
 - feeding behavior, 1095
 - food hoarding, 543
 - nucleus accumbens, 1095
 - opiate agonists, 543
 - striatum, 1095
- Inhibition and stimulation, 1035
 - drug comparisons
 - drug interactions
 - ethanol
 - locomotor activity
 - d*-methamphetamine
- Inhibitory avoidance, 469
 - avoidance learning
 - substance P
- Insulin receptors, 681
 - hypocaloric diets
 - obesity
 - simple carbohydrate comparisons
- Internal clock speed, 1185
 - D₂ receptors
 - dopamine
 - neuroleptics
 - time estimation
- Inter-response time, 145
 - d*-amphetamine
 - bin analysis
 - monkeys
 - Sidman avoidance schedule
- Intestinal distention, 491
 - acarbose
 - dietary starch
- Intracerebral cannula, 487
 - rodents, small
 - unrestrained animals
- Intracranial administration, 717
 - lysergic acid diethylamide (LSD)
 - operant behavior
 - route of administration
- Intracranial self-stimulation, 63
 - DOPAC
 - electrical stimulation
 - in vivo*
 - nigro-striatal pathway
- Intraspecies behavior, 515
 - antidepressants
 - locomotor activity
 - pharmacological analysis
- Intrathecal injection, 483
 - chronic infusion
 - tolerance
- Investigatory behavior, 277
 - locomotor activity
 - multivariate assessment
 - stimulants
- In vitro*, 827
 - metabolic interactions
 - phencyclidine (PCP)
 - Ca⁺⁺-precipitated liver microsomes
 - Δ⁹-tetrahydrocannabinol (Δ⁹-THC)
- In vivo*
 - alpha₂-adrenergic antagonists, 155
 - amphetamine, 155
 - DOPAC concentrations, 63
 - electrical stimulation, 63
 - intracranial self-stimulation, 63
 - locomotor activity, 155
 - naïon-coated electrodes, 325
 - nigro-striatal pathway, 63
 - stereotypy, 155
 - voltammetric recording, 325
- Isocaloric diets, 7
 - bombesin
 - cholecystokinin (CCK)
 - dietary self-selection
- Ketanserin, 111
 - harmine
 - lordosis
 - pireperone
- Ketanserin pretreatment, 135
 - drug discrimination
 - 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH DPAT)
 - tetralin analogues

- Lateral hypothalamus, 59
 - 2-deoxy-D-glucose
 - feeding behavior
 - hyperphagia
 - 5-thioglucose
 - ventromedial hypothalamus
- Lateralized hyperactivity, 263
 - focal brain injury
 - lesions, cortical island
- Lateralized rotation, 689
 - apomorphine
 - postural asymmetry
- Lead retention, 1089
 - behavioral development
 - preweaning lead exposure
- Learned helplessness, 1
 - antidepressants
 - escape deficit
 - inescapable shock
 - serotonergic neurons
- Learning, 141
 - brain iron-deficiency
 - water maze
- Lesions, cortical island, 263
 - focal brain injury
 - lateralized hyperactivity
- Lesions, dorsal raphe nucleus, 1211
 - lesions, locus coeruleus
 - lesions, medial raphe nucleus
 - locomotor activity
 - open field
 - α_2 -receptors
 - sedation, clonidine-induced
- Lesions, 6-hydroxydopamine (6-OHDA), 1307
 - amphetamine
 - dopamine depletion
 - lesions, substantia nigra
 - recovery
 - rotation
- Lesions, kainic acid, 583
 - barrel rotation, 583, 589
 - behavioral changes, 589
 - nicotine, 583
 - prostration, 583
 - receptor changes, 589
 - vasopressin, 583
 - vestibular cerebellum, 583
- Lesions, locus coeruleus, 1211
 - lesions, dorsal raphe nucleus
 - lesions, medial raphe nucleus
 - locomotor activity
 - open field
 - α_2 -receptors
 - sedation, clonidine-induced
- Lesions, medial hypothalamus, 401
 - brain monoamines
 - hyperphagia
 - obesity
- Lesions, medial raphe nucleus, 1211
 - lesions, dorsal raphe nucleus
 - lesions, locus coeruleus
 - locomotor activity
 - open field
 - α_2 -receptors
 - sedation, clonidine-induced
- Lesions, neurotoxic, 191
 - cocaine
 - medial prefrontal cortex
 - presynaptic dopaminergic terminals
 - self-administration, intracranial
- Lesions, nucleus basalis magnocellularis, 293
 - diurnal cycle
 - locomotor activity
- Lesions, paraventricular nucleus (PVN), 381
 - appetite regulation
 - deprivation
 - eating
 - glucoprivic feeding
- Lesions, substantia nigra
 - amphetamine, 1307
 - dopamine depletion, 1307
 - hypertension, 317
 - lesions, 6-hydroxydopamine (6-OHDA), 1307
 - open field, 317
 - recovery, 1307
 - rotation, 1307
 - strain differences, 317
 - striatal dopamine content, 317
- Lever pressing, 973
 - conditioned aversions
 - drug-paired stimuli
 - lithium chloride (LiCl)
 - monkeys
- Licking, 219
 - anhedonia
 - pimozide
 - sucrose concentration
- Limbic structures, 797
 - ethanol tolerance
 - serotonin synthesis
 - vasopressin-like peptides
- Limbic system, 71
 - aggression
 - bull breeds
 - neurotransmitter amino acids
- Liquid diet, 1153
 - 2-deoxy-D-glucose
 - glucoprivation
 - hypophagia
 - water deprivation
- Lithium
 - adjunctive consumption, 1159, 1163
 - alcohol, 1159, 1163
 - drinking, 1159, 1163
 - extinction, 1159, 1163
 - shock, 1163
 - stress, 1163
 - water, 1159
- Lithium-chloride (LiCl), 973
 - conditioned aversions
 - drug-paired stimuli
 - lever pressing
 - monkeys
- Locomotor activity
 - acetylcholine release, 943
 - adenosine receptors, 769
 - alpha₂-adrenergic antagonists, 155
 - age differences, 599
 - amphetamine, 155, 161, 1149
 - anorexia, 99
 - antidepressants, 515
 - antinociception, 599
 - anxiety, 595
 - area postrema, 269
 - atropine, 985
 - body temperature, 1293
 - brain noradrenergic system, 411
 - caffeine, 1271
 - circling behavior, 1021
 - clonidine, 985
 - conditioned place aversion, 1041
 - conditioned place preference, 1041
 - conditioned taste aversion, 269
 - convulsions, 595
 - diisopropylfluorophosphate (DFP), 1293
 - 6,7-dimethoxy, 4 ethyl β -carboline carboxylic acid methyl ester (DMCM), 595
 - diurnal cycle, 293
 - drug comparisons, 1035
 - drug interactions, 943, 985, 1035
 - eating, 99, 1149
 - L-erythro-dihydroxyphenylserine (L-erythro-DOPS), 411
 - ethanol, 1035
 - fixed ratio/interval schedule, 375
 - FG 7142, 99
 - grooming, 99
 - heart rate, 1293
 - hyperphagia, 99
 - hypothermia, 769
 - inbred strains, 769
 - inhibition and stimulation, 1035
 - intraspecies behavior, 515
 - investigatory behavior, 277
 - in vivo, 155
 - lesions, dorsal raphe nucleus, 1211
 - lesions, locus coeruleus, 1211
 - lesions, medial raphe nucleus, 1211
 - lesions, nucleus basalis magnocellularis, 293
 - metabolic rate, 161
 - d*-methamphetamine, 1035
 - N-methyl aspartate, 943
 - methylxanthines, 769
 - midazolam, 99
 - morphine, 599
 - multivariate assessment, 277
 - muscarinic receptors, 1293
 - naltrexone, 595
 - nicotine, 1041
 - nucleus accumbens, 1149
 - open field, 1211
 - pentobarbital, 375
 - pharmaco-ethological analysis, 515
 - prenatal alcohol exposure, 1021
 - propunishment, 595
 - ³H-quinuclidinyl benzilate (³H-QNB) binding, 1293
 - rearing, 99
 - α_2 -receptors, 1211
 - respiration rate, 1293
 - scopolamine, 269
 - secobarbital, 375
 - sedation, clonidine-induced, 1211
 - stereoisomers, 375
 - stereotypy, 155, 985
 - stimulants, 277
 - strain differences, 1271
 - theobromine, 769
 - theophylline, 1271
 - tolerance, 1293
 - variable interval schedule, 375
- Locomotor activity, drug-induced, 255
 - dopamine autoreceptor agonists
 - exploratory activity
- Locomotor behavior, 233
 - opiates
 - psychostimulants
 - sympathomimetics

- Locomotor excitation, 29
 - alternation
 - amphetamine
 - perseveration
- Locomotor hyperactivity, 297
 - animal model
 - Huntington's disease
 - neural transplants
- Lordosis, 111
 - harmine
 - ketanserin
 - pirenerone
- Lordosis disruption, 857
 - midbrain infusions
 - procaine
 - tetrodotoxin
- LY 171555, 1117
 - dopamine systems
 - radial arm maze
- Lysergic acid diethylamide (LSD)
 - intracranial administration, 717
 - operant behavior, 717
 - pizotyline, 227
 - route of administration, 717
 - stimulus control, 227
 - verapamil, 227

- Magnesium, 1195
 - acute administration
 - aggression
 - chronic administration
 - tolerance
- Marijuana
 - adrenergic receptors, 763
 - behavioral analysis, 577
 - caloric intake, 577
 - dopamine receptors, 763
 - eating, 577
 - human studies, males, 577
 - perinatal exposure, 763
 - tyrosine hydroxylase activity, 763
- Marijuana smoking, 659
 - human studies
 - subjective rating
 - tobacco smoking
- Maximal electroshock, 1059
 - anticonvulsant effects
 - bicuculline
 - drug interactions
 - GABA_A receptors
 - pentobarbital
 - phenobarbital
 - picrotoxin
 - seizures
- Maze learning, 673
 - age differences
 - avoidance conditioning
 - memory
 - scopolamine
- Medial hypothalamus, 1223
 - deprivation
 - eating
 - norepinephrine (NE)
 - paraventricular nucleus (PVN)
 - serotonin
- Medial prefrontal cortex, 191
 - cocaine
 - lesions, neurotoxic
 - presynaptic dopaminergic terminals
 - self-administration, intracranial

- Mediodorsal nucleus of the thalamus, 423
 - blood pressure
 - chemical stimulation
 - heart rate
 - rabbits
- Memory
 - age differences, 673
 - avoidance conditioning, 673
 - chicks, 823
 - maze learning, 673
 - scopolamine, 673
 - testosterone, 823
- Memory effects, time related, 1125
 - consolidation
 - passive avoidance behavior
 - retrieval
 - vasopressin
 - vasopressin analogues
- Memory function, 1137
 - glycoprotein fucosylation
- Metabolic interactions, 827
 - in vitro
 - phencyclidine (PCP)
 - Ca²⁺-precipitated liver microsomes
 - Δ⁹-tetrahydrocannabinol (Δ⁹-THC)
- Metabolic rate, 161
 - amphetamine
 - locomotor activity
- Metabolic tolerance, 1013
 - alcohol dehydrogenase
 - alcohol elimination rate
 - alcohol-preferring rats
 - free-choice drinking
- Metazocine, 785
 - drug discrimination
 - monkeys
 - self-administration
 - stimulus properties
- Methadone, 149
 - drug interactions
 - imipramine
 - pigeons
 - variable interval schedule
- d*-Methamphetamine, 1035
 - drug comparisons
 - drug interactions
 - ethanol
 - inhibition and stimulation
 - locomotor activity
- [D-Ala²]-Methionine enkephalinamide (DALA), 641
 - anesthesia
 - antinociception
 - cardiovascular system
 - renal sympathetic nerve
- Method
 - autoradiography, 1051
 - Behavioral Pattern Monitor, 277
 - color tracing, 117
 - formalin test, 883
 - gas chromatography, 827
 - high performance liquid chromatography (HPLC), 415, 865, 903
 - hot-plate test, 883
 - kainate lesioning, 583, 589
 - key peck, 371
 - pendulum technique, 329
 - platform technique, 329
 - radio-frequency lesions, 1279
 - Sidman avoidance schedule, 145
 - tail-flick test, 883
- 5-Methoxy-N,N-dimethyltryptamine (5-OMe DMT), 1207
 - dose-dependent effects
 - drug discrimination
 - Sidman avoidance schedule, 145
 - serotonin antagonists
 - stimulus properties
- 2-Methylpiperidone, 843
 - cytosine
 - dogs
 - fourth ventricle
 - high/low affinity sites
 - nicotine
- α-Methyl-p-tyrosine (α-MPT), 949
 - catecholamines
 - 6-hydroxydopamine (6-OHDA)
 - seizures, pentylentetrazol (PTZ) induced
- Methylxanthines, 769
 - adenosine receptors
 - hypothermia
 - inbred strains
 - locomotor activity
 - theobromine
- Methysergide, 23
 - drug interactions
 - 5-hydroxytryptamine (5-HT)
 - hyperdipsia
 - hypophagia
 - propranolol
- Midazolam, 99
 - anorexia
 - eating
 - FG 7142
 - grooming
 - hyperphagia
 - locomotor activity
 - rearing
- Midbrain infusions, 857
 - lordosis disruption
 - procaine
 - tetrodotoxin
- Model of depression, 805
 - antidepressants
 - serotonergic receptors
- Monkeys
 - d*-amphetamine, 145
 - bin analysis, 145
 - conditioned aversions, 973
 - delayed performance, 201
 - drug discrimination, 785
 - drug interactions, 185
 - drug-paired stimuli, 973
 - inter-response time, 145
 - lever pressing, 973
 - lithium chloride (LiCl), 973
 - metazocine, 785
 - nicotine, 185
 - phencyclidine (PCP), 185, 201
 - repeated acquisitions, 185, 201
 - response chains, 185, 201
 - retention, 201
 - self-administration, 785
 - Sidman avoidance schedule, 145
 - stimulus properties, 785
- Morphine
 - age differences, 599
 - analgesia, 215, 1201
 - antinociception, 599, 835
 - antinociceptive system, 533
 - benzodiazepine receptors, 215
 - cholecystokinin (CCK), 1067

- classical conditioning, 1169, 1201
- conditioned place preference, 1101
- drinking, 1001
- drug comparisons, 835
- drug discrimination, 209
- drug interactions, 835
- drug reinforcement, 1101, 1169
- environmental specific cues, 1201
- exploratory behavior, 1169
- habituation, 1169, 1201
- hamsters, 1067
- hyperactivity, 1067
- hypoactivity, 1067
- locomotor activity, 599
- naloxone antagonism, 209
- naloxone-precipitated withdrawal, 1001
- opiate tolerance, 533
- physical dependence, 1001
- pigeons, 209
- place preference, 1169
- reinforcement threshold, 1263
- response rate, 1263
- self-stimulation, 1263
- single-trial, 1101
- snails, 1201
- stimulation-produced analgesia, 533
- stress, 1201
- sucrose, 1001
- tizanidine, 835
- tolerance, 835, 1201
- withdrawal, precipitated, 1263
- withdrawal, spontaneous, 1263
- Morphine dependent rats, 953
 - angiotensin converting enzyme (ACE) activity
 - aspartic acid
 - brain asparaginase
 - naloxone
 - plasma cortisol level
- Motility, 775
 - cold-restraint stress
 - gastric motility
- Motor activity
 - calcium antagonists, 45
 - chronic administration, 129
 - dopamine receptors, 129
 - drug interactions, 45
 - phencyclidine (PCP), 45
 - phenylethylamine (PEA), 129
 - sensitization, 129
- Motor effects, 791
 - haloperidol
 - neuroleptics
 - operant responding
- MSH-release inhibiting factor-1 (MIF-1), 757
 - apomorphine-induced stereotypy
 - dopaminergic neuron activity
 - Tyr-MSH-release inhibiting factor-1 (Tyr-MIF-1)
- Tyr-MSH-release inhibiting factor-1 (Tyr-MIF-1)
 - apomorphine-induced stereotypy, 757
 - dopaminergic neuron activity, 757
 - endogenous opiates, 1303
 - MSH-release inhibiting factor-1 (MIF-1), 757
 - opiate receptor sites, 1303
 - peptide interactions, 1303
- Multivariate assessment, 277
 - investigatory behavior
- locomotor activity stimulants
- Muricide, 95
 - environmental influences
 - GABA receptors
- Muscarinic agents, 171
 - analgesia, stress-induced
 - cold water swim
 - hyperphagia
 - hypothermia
 - pain
- Muscarinic receptors, 1293
 - body temperature
 - diisopropylfluorophosphate (DFP)
 - heart rate
 - locomotor activity
 - ³H-quinuclidinyl benzilate (³H-QNB) binding
 - respiration rate
 - tolerance
- Nafion-coated electrodes, 325
 - in vivo
 - voltammetric recording
- Nalbuphine, 629
 - brain stimulation
 - drug interactions
 - reward threshold
 - tripelennamine
- Naloxone
 - adrenergic receptors, 989
 - amnesia, 567
 - amphetamine, 123
 - angiotensin converting enzyme (ACE) activity, 953
 - anisomycin, 567
 - aspartic acid, 953
 - behavioral despair test, 511
 - brain asparaginase, 953
 - clonidine, 989
 - continuous infusion, 989
 - cycloheximide, 567
 - drinking, 697
 - drug interactions, 567, 989
 - eating motivation, 123
 - fenfluramine, 123
 - H₂-receptor blockers, 511
 - morphine dependent rats, 953
 - naltrexone, 123
 - opiate abstinence syndrome, 989
 - palatability, 697
 - passive avoidance, 567
 - plasma cortisol level, 953
 - satiation, 697
 - sequential presentation, 697
 - shuttle avoidance, 567
- Naloxone antagonism, 209
 - drug discrimination
 - morphine
 - pigeons
- Naloxone-precipitated withdrawal, 1001
 - drinking
 - morphine
 - physical dependence
 - sucrose
- Naltrexone
 - amphetamine, 123
 - anxiety, 595
 - CGS 8216, 439
 - convulsions, 595
- 6,7-dimethoxy, 4 ethyl β -carboline carboxylic acid methyl ester (DMCM), 595
 - drug interactions, 439
 - eating motivation, 123
 - endogenous opioids, 573
 - ethanol, 439
 - fenfluramine, 123
 - locomotor activity, 595
 - naloxone, 123
 - prenatal stress, 573
 - propunishment, 595
 - satiety, 123
 - sexual behavior differentiation, 573
 - shock avoidance, 439
 - timeout from avoidance, 439
- Neonates, 1145
 - benzodiazepines
 - convulsions
 - hyperactivity
 - type 2 receptors
- Neural transplants, 297
 - animal model
 - Huntington's disease, 297
 - locomotor hyperactivity, 297
- Neurobiological responses, 41
 - immobilization, acute
 - social isolation
- Neuroleptics
 - apomorphine, 473, 503
 - behavioral deficits, 503
 - cataleptic behavior, 463
 - cognitive deficits, 503
 - D₂ receptors, 1185
 - dopamine, 1185
 - dopamine receptors, 473
 - drug interactions, 463
 - exploratory behavior, 473
 - haloperidol, 791
 - internal clock speed, 1185
 - motor effects, 791
 - operant behavior, 503
 - operant responding, 791
 - prostaglandins, 463
 - time estimation, 1185
- Neurotransmitter amino acids, 71
 - aggression
 - bull breeds
 - limbic system
- Nicotine
 - barrel rotation, 583
 - body weight, 1131
 - caloric intake, 1131
 - conditioned place aversion, 1041
 - conditioned place preference, 1041
 - cytisine, 843
 - dogs, 843
 - drug interactions, 185
 - finger tapping, 727
 - fourth ventricle, 843
 - high/low affinity sites, 843
 - human studies, non-smokers, 727
 - lesions, kainic acid, 583
 - locomotor activity, 1041
 - 2-methylpiperidone, 843
 - monkeys, 185
 - phencyclidine (PCP), 185
 - physical activity, 1131
 - prostration, 583
 - rats, females, 1131
 - repeated acquisition, 185
 - response chain, 185

- vasopressin, 583
- vestibular cerebellum, 583
- Nicotine absorption, 1181
 - buccal mucosa
 - human studies
 - passive smoking
- Nicotine gum, 879
 - electroencephalographic effects
 - human studies, smokers
 - tobacco deprivation
- Nigro-striatal pathway, 63
 - DOPAC concentrations
 - electrical stimulation
 - intracranial self-stimulation
 - in vivo
- Nociception sensitivity, 883
 - 5-hydroxytryptamine
 - hyperalgesia
 - hypoalgesia
 - 8-OH-2-(di-n-propylamino)tetralin (8-OH-DPAT)
 - route of administration
- Noradrenergic denervation, 743
 - α_1 -adrenoceptors
 - β -adrenoceptors
 - functional sensitivity
 - N-(2-chloroethyl)-N-ethyl-2-bromo-benzylamine (DSP-4)
- Norepinephrine (NE)
 - adenylate cyclase, 223
 - 3 H-cyclic AMP, 223
 - deprivation, 1223
 - eating, 1223
 - medial hypothalamus, 1223
 - paraventricular nucleus (PVN), 1223
 - REM sleep deprivation, 223
 - serotonin, 1223
- Nucleus accumbens
 - amphetamine, 1149
 - dopamine metabolism, 1095
 - eating, 1149
 - feeding behavior, 1095
 - ingestion, 1095
 - locomotor activity, 1149
 - striatum, 1095
- Obesity
 - brain monoamines, 401
 - hyperphagia, 401
 - hypocaloric diets, 681
 - insulin receptors, 681
 - lesions, medial hypothalamus, 401
 - simple carbohydrate comparisons, 681
- Offspring behavior, 873
 - 5-HT syndrome
 - open-field behavior
 - prenatal stress
- 8-OH-2-(di-n-propylamino)tetralin (8-OH-DPAT), 883
 - 5-hydroxytryptamine (5-HT)
 - hyperalgesia
 - hypoalgesia
 - nociception sensitivity
 - route of administration
- Open field
 - hypertension, 317
 - lesions, dorsal raphe nucleus, 1211
 - lesions, locus coeruleus, 1211
 - lesions, medial raphe nucleus, 1211
 - lesions, substantia nigra, 317
 - locomotor activity, 1211
- α_2 -receptors, 1211
- sedation, clonidine induced, 1211
- strain differences, 317
- striatal dopamine content, 317
- Open-field activity, 289
 - genetic behavior
 - genetic breeding
 - habituation
 - pharmacogenetics
- Open-field behavior, 873
 - 5-HT syndrome
 - offspring behavior
 - prenatal stress
- Operant behavior
 - apomorphine, 503
 - behavioral deficits, 503
 - cognitive deficits, 503
 - differential reinforcement of low rate of response (DRL), 1191
 - fixed ratio performance, 1191
 - intracranial administration, 717
 - lysergic acid diethylamide (LSD), 717
 - neuroleptics, 503
 - 3-quinuclidinyl benzilate (QNB), 1191
 - route of administration, 717
 - schedule dependent effects, 1191
- Operant responding, 791
 - haloperidol
 - motor effects
 - neuroleptics
- Opiate abstinence syndrome, 989
 - adrenergic receptors
 - clonidine
 - continuous infusion
 - drug interactions
 - naloxone
- Opiate agonists, 543
 - deer mouse
 - food hoarding
 - ingestion
- Opiate receptor sites, 1303
 - endogenous opiates
 - peptide interactions
 - Tyr-MSH-release inhibiting factor-1 (Tyr-MIF-1)
- Opiate receptors, 959
 - circling, opiate-induced
 - dopaminergic system
 - ventral tegmental area
- Opiate tolerance, 533
 - antinociceptive system
 - morphine
 - stimulation-produced analgesia
- Opiates
 - drug interactions, 1007
 - endogenous opiates, 1007
 - locomotor behavior, 233
 - postpartum aggression, 1007
 - psychostimulants, 233
 - sympathomimetics, 233
- Opioid agonists, 77
 - drinking
 - water balance
- Opioid peptides, 967
 - anorexia
 - fenfluramine
 - gastrointestinal tract
- Oxytocin, 107
 - corticosterone
 - psychological stressor
- P-chlorophenylalanine (PCPA), 415
 - shock, uncontrollable
 - stress
- Pain, 171
 - analgesia, stress-induced
 - cold water swim
 - hyperphagia
 - hypothermia
 - muscarinic agents
- Palatability, 697
 - drinking
 - naloxone
 - satiation
 - sequential presentation
- Paraventricular nucleus (PVN), 1223
 - deprivation
 - eating
 - medial hypothalamus
 - norepinephrine (NE)
 - serotonin
- Partial reinforcement extinction effect, 1231
 - anhedonia
 - haloperidol
 - reward omission, periodic
 - water reinforcement
- Passive avoidance
 - amnesia, 567
 - anisomycin, 567
 - cycloheximide, 567
 - drug interactions, 567
 - exponential data analysis, 979
 - naloxone, 567
 - shuttle avoidance, 567
 - step-through latencies, 979
- Passive avoidance behavior, 1125
 - consolidation
 - memory effects, time related
 - retrieval
 - vasopressin
 - vasopressin analogues
- Passive smoking, 1181
 - buccal mucosa
 - human studies
 - nicotine absorption
- Pavlovian conditioning, 1111
 - ethanol
 - ethanol withdrawal
 - 3 H-PCP binding potency, 1051
 - autoradiography
 - discriminative stimulus properties
 - phencyclidine (PCP)-related compounds
- Pemoline, 933
 - hotplate test
 - self-injurious behavior
 - stereotypy
- Pentobarbital
 - anticonvulsant effects, 1059
 - bicuculline, 1059
 - drug interactions, 1059
 - fixed ratio/interval schedule, 375
 - GABA_A receptors, 1059
 - locomotor activity, 375
 - maximal electroshock, 1059
 - phenobarbital, 1059
 - picrotoxin, 1059
 - secobarbital, 375
 - seizures, 1059
 - stereoisomers, 375
 - variable interval schedule, 375

- Peptide**
- adrenocorticotrophic hormone 1–24 (ACTH 1–24), 753, 1303
 - adrenocorticotrophic hormone 1–39 (ACTH 1–39), 1303
 - alpha-methyl-p-tyrosine, 959
 - arginine vasopressin (AVP), 797, 1125
 - arginine vasopressin (1–8) (AVP-(1–8)), 1125
 - arginine vasopressin (4–8) (AVP-(4–8)), 1125
 - arginine vasopressin (4–9) (AVP-(4–9)), 1125
 - arginine vasopressin (5–8) (AVP-(5–8)), 1125
 - arginine vasopressin (5–9) (AVP-(5–9)), 1125
 - bombesin, 7
 - cholecystokinin (CCK), 7, 1067
 - cholecystokinin octapeptide (CCK-8), 1303
 - cyclo(leucyl-glycyl) (cLG), 1279
 - d-Ala(2)-d-Leu(5)-enkephalin (DADLE), 959
 - [D-Pen²,D-Pen⁵-enkephalin] (DPDPE), 77, 1303
 - desglycinamide-arginine-vasopressin (DGAVP), 797
 - dynorphin (1–13), 77, 959
 - FMRF-NH₂, 1303
 - morphiceptin, 1303
 - MSH-release inhibiting factor-1 (MIF-1), 757, 1303
 - Tyr-MSH-release inhibiting factor-1 (Tyr-MIF-1), 757, 1303
 - substance P, 469
 - (Tyr-D-Ala-Gly-(Me)Phe-Gly-ol) (DAGO), 1303
 - (Tyr-D-Ala-Gly-(Me)Phe-Met-ol) (FK33824), 1303
 - vasopressin, 583, 589
 - Peptide interactions, 1303**
 - endogenous opiates
 - opiate receptor sites
 - Tyr-MSH-release inhibiting factor-1 (Tyr-MIF-1)
 - Perinatal exposure, 763**
 - adrenergic receptors
 - dopamine receptors
 - marijuana
 - tyrosine hydroxylase activity
 - Perioral behaviors, 1217**
 - cholinesterase inhibitors
 - physostigmine
 - tardive dyskinesia
 - Perseveration, 29**
 - alternation
 - amphetamine
 - locomotor excitation
 - Pharmaco-ethological analysis, 515**
 - antidepressants
 - intraspecies behavior
 - locomotor activity
 - Pharmacogenetics, 289**
 - genetic behavior
 - genetic breeding
 - habituation
 - open-field activity
 - Phencyclidine (PCP)**
 - acoustic startle, 1175
 - amphetamine, 1175
 - calcium antagonists, 45
 - cocaine, 1175
 - cross-tolerance, 1175
 - delayed performance, 201
 - drug discrimination, 117
 - drug interactions, 45, 185
 - habituation, 1175
 - in vitro, 827
 - metabolic interactions, 827
 - monkeys, 185, 201
 - motor activity, 45
 - nicotine, 185
 - pigeons, 117
 - plasma phencyclidine, 117
 - Ca²⁺-precipitated liver microsomes, 827
 - repeated acquisition, 185, 201
 - response chains, 185, 201
 - retention, 201
 - sensitization, 1175
 - Δ⁹-tetrahydrocannabinol (Δ⁹-THC), 827
 - tolerance, 1175
 - Phencyclidine (PCP) metabolites, 359**
 - age differences
 - cats
 - tolerance
 - Phencyclidine (PCP)-related compounds, 1051**
 - autoradiography
 - discriminative stimulus properties
 - ³H-PCP binding potency
 - Phenobarbital**
 - anticonvulsant effects, 1059
 - bicuculline, 1059
 - delayed-matching-to-sample, 929
 - drug interactions, 929, 1059
 - GABA_A receptors, 1059
 - maximal electroshock, 1059
 - pentobarbital, 1059
 - phenytoin, 929
 - picROTOXIN, 1059
 - seizures, 1059
 - valproic acid, 929
 - Phentermine, 623**
 - abrupt feeding
 - food deprivation
 - self-administration
 - Phenylethylamine (PEA)**
 - amphetamine, 711
 - anorexia, drug induced, 711
 - chronic administration, 129
 - dopamine receptors, 129
 - hyperactivity, drug induced, 711
 - motor activity, 129
 - sensitization, 129
 - Phenytoin, 929**
 - delayed-matching-to-sample
 - drug interactions
 - phenobarbital
 - valproic acid
 - Physical activity, 1131**
 - body weight
 - caloric intake
 - nicotine
 - rats, females
 - Physical dependence, 1001**
 - drinking
 - morphine
 - naloxone-precipitated withdrawal
 - sucrose
 - Physostigmine, 1217**
 - cholinesterase inhibitors
 - perioral behaviors
 - tardive dyskinesia
 - Picrotoxin, 1059**
 - anticonvulsive effects
 - bicuculline
 - drug interactions
 - GABA_A receptors
 - maximal electroshock
 - pentobarbital
 - phenobarbital
 - seizures
 - Pigeons**
 - anxiety, 371
 - anxiolytic drugs, 371
 - beta-blockers, 371
 - delayed-matching-to-sample, 929
 - drug discrimination, 117, 209
 - drug interactions, 149, 929
 - imipramine, 149
 - methadone, 149
 - morphine, 209
 - naloxone antagonism, 209
 - phencyclidine (PCP), 117
 - phenobarbital, 929
 - phenytoin, 929
 - plasma phencyclidine, 117
 - punished responding, 371
 - variable interval schedule, 149
 - Pimozide**
 - anhedonia, 219, 615
 - duration of response, 615
 - force of response, 615
 - licking, 219
 - response rate, 615
 - sucrose concentration, 219
 - Piracetam-like compounds, 925**
 - amnesia
 - drug interactions
 - hemicholinium-3
 - Pirenperone, 111**
 - harmine
 - ketanserin
 - lordosis
 - Pizotyline, 227**
 - lysergic acid diethylamide (LSD)
 - stimulus control
 - verapamil
 - Place preference, 1169**
 - classical conditioning
 - drug reinforcement
 - exploratory behavior
 - habituation
 - morphine
 - Plasma cortisol level, 953**
 - angiotensin converting enzyme (ACE) activity
 - aspartic acid
 - brain asparaginase
 - morphine dependent rats
 - naloxone
 - Plasma ethanol levels, 889**
 - EKG alpha activity
 - ethanol-induced euphoria
 - human studies
 - Plasma levels, 365**
 - diphenhydramine
 - driving related tasks
 - human studies, males
 - Plasma phencyclidine, 117**
 - drug discrimination
 - phencyclidine (PCP)
 - pigeons

- Polydipsia, 431
 - benzodiazepines
 - conditioned taste aversion
 - drinking
 - two-bottle choice paradigm
- Postpartum aggression, 1007
 - drug interactions
 - endogenous opioids
 - opiates
- Postural asymmetry, 689
 - apomorphine
 - lateralized rotation
- ³H-Prazosin, 329
 - adrenoceptors
 - antidepressants
 - ³H-dihydroalprenolol (³H-DHA)
 - binding
 - REM sleep deprivation
- Ca⁺⁺-Precipitated liver microsomes, 827
 - in vitro
 - metabolic interactions
 - phencyclidine (PCP)
 - Δ⁹-tetrahydrocannabinol (Δ⁹-THC)
- Prenatal alcohol exposure, 1021
 - circling behavior
 - locomotor activity
- Prenatal stress
 - endogenous opioids, 573
 - 5-HT syndrome, 873
 - naltrexone, 573
 - offspring behavior, 873
 - open-field behavior, 873
 - sexual behavior differentiation, 573
- Presynaptic dopaminergic terminals, 191
 - cocaine
 - lesions, neurotoxic
 - medial prefrontal cortex
 - self-administration, intracranial
- Prewaning lead exposure, 1089
 - behavioral development
 - lead retention
- Procaine, 857
 - lordosis disruption
 - midbrain infusions
 - tetrodotoxin
- Prolactin secretion, 457
 - bupirone
 - corticosterone secretion
 - stress
- Propranolol, 23
 - drug interactions
 - 5-hydroxytryptamine (5-HT)
 - hyperdipsia
 - hypophagia
 - methysergide
- Propunishment, 595
 - anxiety
 - convulsions
 - 6,7-dimethoxy, 4 ethyl β-carboline
 - carboxylic acid methyl ester (DMCM)
 - locomotor activity
 - naltrexone
- Prostaglandins
 - cataleptic behavior, 463
 - drug interactions, 463
 - neuroleptics, 463
 - pyrexia, 347
 - subdiencephalic rat brain, 347
- Prostaglandin (PGE₁), 353
 - cochlear nucleus
 - pyrexia
- Prostration, 583
 - barrel rotation
 - lesions, kainic acid
 - nicotine
 - vasopressin
 - vestibular cerebellum
- Psychological stressor, 107
 - corticosterone
 - oxytocin
- Psychostimulants, 233
 - locomotor behavior
 - opiates
 - sympathomimetics
- Punished responding, 371
 - anxiety
 - anxiolytic drugs
 - beta-blockers
 - pigeons
- Purine nucleotide binding, 733
 - appetite suppressants
 - brown adipose tissue (BAT)
- Pyrexia
 - cochlear nucleus, 353
 - prostaglandin, 347
 - prostaglandin (PGE₁), 353
 - subdiencephalic rat brain, 347
- Pyridostigmine, 1071
 - cholinesterase inhibition
 - clinical chemistry
 - heat
 - thermoregulation
- 3-Quinuclidinyl benzilate (QNB), 1191
 - differential reinforcement of low rate of response (DRL)
 - fixed ratio performance
 - operant behavior
 - schedule dependent effects
- ³H-Quinuclidinyl benzilate (³H-QNB)
 - binding, 1293
 - body temperature
 - diisopropylfluorophosphate (DFP)
 - heart rate
 - locomotor activity
 - muscarinic receptors
 - respiration rate
 - tolerance
- Rabbits
 - analgesiometry, 481
 - blood pressure, 423
 - chemical stimulation, 423
 - ear-withdrawal, 481
 - heart rate, 423
 - hippocampal 5-HT activity, 781
 - mediodorsal nucleus of the thalamus, 423
 - tonic immobility, 781
- Radial arm maze, 1117
 - dopamine systems
 - LY 171555
- Radial arm maze performance, 703
 - ethanol
 - sex differences
- Radial maze performance, 521
 - BW813U
 - choline acetyltransferase (ChAT)
 - inhibitor
 - spatial memory
- Rapid eye movement (REM) sleep, 1253
 - cholinomimetics
 - chronic microinfusion
- Rat/pigeon comparisons, 393
 - drug discrimination
 - hexahydrocannabinol stereochemistry
- Rats, females, 1131
 - body weight
 - caloric intake
 - nicotine
 - physical activity
- Rearing, 99
 - anorexia
 - eating
 - FG 7142
 - grooming
 - hyperphagia
 - locomotor activity
 - midazolam
- Receptor changes, 589
 - barrel rotation
 - behavioral changes
 - lesions, kainic acid
- α₂-Receptors, 1211
 - lesions, dorsal raphe nucleus
 - lesions, locus coeruleus
 - lesions, medial raphe nucleus
 - locomotor activity
 - open field
 - sedation, clonidine induced
- Recovery, 1307
 - amphetamine
 - dopamine depletion
 - lesions, 6-hydroxydopamine (6-OHDA)
 - lesions, substantia nigra
 - rotation
- Reinforcement threshold, 1263
 - morphine
 - response rate
 - self-stimulation
 - withdrawal, precipitated
 - withdrawal, spontaneous
- REM sleep deprivation
 - adenylate cyclase, 223
 - adrenoceptors, 329
 - antidepressants, 329
 - ³H-cyclic AMP, 223
 - ³H-dihydroalprenolol (³H-DHA)
 - binding
 - norepinephrine (NE), 223
 - ³H-prazosin, 329
- Renal sympathetic nerve, 641
 - anesthesia
 - antinociception
 - cardiovascular system
 - [D-Ala²]-methionine enkephalinamide (DALA)
- Repeated acquisition
 - delayed performance, 201
 - drug interactions, 185
 - monkeys, 185, 201
 - nicotine, 185
 - phencyclidine (PCP), 185, 201
 - response chains, 185, 201
 - retention, 201
- Reproduction, 449
 - drinking
 - hamsters
 - high-caloric-fluids
 - social stress

- Respiration rate, 1293
 - body temperature
 - diisopropylfluorophosphate (DFP)
 - heart rate
 - locomotor activity
 - muscarinic receptors
 - ³H-quinuclidinyl benzilate (³H-QNB)
 - binding
 - tolerance
- Response bias, 633
 - delayed response
 - discrimination
 - scopolamine
 - working memory
- Response chains
 - delayed performance, 201
 - drug interactions, 185
 - monkeys, 185, 201
 - nicotine, 185
 - phencyclidine (PCP), 185, 201
 - repeated acquisition, 185, 201
 - retention, 201
- Response rate, 615
 - anhedonia, 615
 - duration of response, 615
 - force of response, 615
 - morphine, 1263
 - pimozide, 615
 - reinforcement threshold, 1263
 - self-stimulation, 1263
 - withdrawal, precipitated, 1263
 - withdrawal, spontaneous, 1263
- Restraint stress, 1083
 - ulcer proliferation
 - voluntary ethanol consumption
- Retention, 201
 - delayed performance
 - monkeys
 - phencyclidine (PCP)
 - repeated acquisition
 - response chains
- Retinol palmitate, 1285
 - cholesterol
 - dietary manipulation
 - essential fatty acids
 - ethanol preference
 - hamsters
- Retrieval, 1125
 - consolidation
 - memory effects, time related
 - passive avoidance behavior
 - vasopressin
 - vasopressin analogues
- Reverse handedness, 651
 - appetitive learning
 - brain DNA
 - DNA synthesis
- Reward omission, periodic, 1231
 - anhedonia
 - haloperidol
 - partial reinforcement extinction effect
 - water reinforcement
- Reward threshold, 629
 - brain stimulation
 - drug interactions
 - nalbuphine
 - tripelennamine, 629
- Rodents, small, 487
 - intracerebral cannula
 - unrestrained animals
- Rotation, 1307
 - amphetamine
 - dopamine depletion
 - lesions, 6-hydroxydopamine (6-OHDA)
 - lesions, substantia nigra
 - recovery
- Route of administration
 - 5-hydroxytryptamine, 883
 - hyperalgesia, 883
 - hypoalgesia, 883
 - intracranial administration, 717
 - lysergic acid diethylamide (LSD), 717
 - nociception sensitivity, 883
 - 8-OH-2-(di-n-propylamino)tetralin (8-OH-DPAT), 883
 - operant behavior, 717
- Saccharin consumption, 341
 - CGS 8216
 - drinking
- Satiation, 697
 - drinking
 - naloxone
 - palatability
 - sequential presentation
- Satiety, 123
 - amphetamine
 - eating motivation
 - fenfluramine
 - naloxone
 - naltrexone
- Schedule-controlled behavior, 537
 - benzodiazepine antagonists
 - drug interactions
- Schedule dependent effects, 1191
 - differential reinforcement of low rate of response (DRL)
 - fixed ratio performance
 - operant behavior
 - 3-quinuclidinyl benzilate (QNB)
- Scopolamine
 - age differences, 673
 - area postrema, 269
 - avoidance conditioning, 673
 - conditioned taste aversion, 269
 - delayed response, 633
 - discrimination, 633
 - locomotor activity, 269
 - maze learning, 673
 - memory, 673
 - response bias, 633
 - working memory, 633
- Secobarbital, 375
 - fixed ratio/interval schedule
 - locomotor activity
 - pentobarbital
 - stereoisomers
 - variable interval schedule
- Sedation, clonidine-induced, 1211
 - lesions, dorsal raphe nucleus
 - lesions, locus coeruleus
 - lesions, medial raphe nucleus
 - locomotor activity
 - open field
 - α_2 -receptors
- Sedation hypnosis, 333
 - circadian rhythm
 - sleep time
 - strain differences
- Seizures, 1059
 - anticonvulsant effects
 - bicuculline
 - drug interactions
 - GABA_A receptors
 - maximal electroshock
 - pentobarbital
 - phenobarbital
 - picrotoxin
- Seizures, pentylenetetrazol (PTZ) induced, 949
 - catecholamines
 - 6-hydroxydopamine (6-OHDA)
 - α -methyl-p-tyrosine (α -MPT)
- Selective breeding, 1077
 - chlordiazepoxide-induced sleep
 - GABAergic drugs
- Self-administration
 - abrupt refeeding, 623
 - cocaine, 497
 - drug discrimination, 785
 - food deprivation, 623
 - haloperidol, 497
 - metazocine, 785
 - monkeys, 785
 - phentermine, 623
 - sex differences, 497
 - stimulus properties, 785
 - tamoxifen, 497
- Self-administration, intracranial, 191
 - cocaine
 - lesions, neurotoxic
 - medial prefrontal cortex
 - presynaptic dopaminergic terminals
- Self-injurious behavior, 933
 - hotplate test
 - pemoline
 - stereotypy
- Self-stimulation, 1263
 - morphine
 - reinforcement threshold
 - response rate
 - withdrawal, precipitated
 - withdrawal, spontaneous
- Sensitization
 - acoustic startle, 1175
 - amphetamine, 1175
 - chronic administration, 129
 - cocaine, 1175
 - cross-tolerance, 1175
 - dopamine receptors, 129
 - habituation, 1175
 - motor activity, 129
 - phencyclidine (PCP), 1175
 - phenylethylamine (PEA), 129
 - tolerance, 1175
- Sequential presentation, 697
 - drinking
 - naloxone
 - palatability
 - satiation
- Serotonergic neurons, 1
 - antidepressants
 - escape deficits
 - inescapable shock
 - learned helplessness
- Serotonergic receptors, 805
 - antidepressants
 - model of depression
- Serotonin, 1223
 - deprivation
 - eating
 - medial hypothalamus
 - norepinephrine (NE)
 - paraventricular nucleus (PVN)

- Serotonin antagonists, 1207
 - dose-dependent effects
 - drug discrimination
 - 5-methoxy-N,N-dimethyltryptamine (5-OMe DMT)
 - stimulus properties
- Serotonin synthesis, 797
 - ethanol tolerance
 - limbic structures
 - vasopressin-like peptides
- Sex differences
 - cocaine, 497
 - ethanol, 703
 - haloperidol, 497
 - radial arm maze performance, 703
 - self-administration, 497
 - tamoxifen, 497
- Sexual behavior differentiation, 573
 - endogenous opioids
 - naltrexone
 - prenatal stress
- Shock, 1163
 - adjunctive consumption
 - alcohol
 - drinking
 - extinction
 - lithium
 - stress
- Shock avoidance, 439
 - CGS 8216
 - drug interactions
 - ethanol
 - naltrexone
 - timeout from avoidance
- Shock escape learning, 693
 - apomorphine
 - dopaminergic mechanisms
- Shock, uncontrollable, 415
 - p-chlorophenylalanine (PCPA)
 - stress
- Shuttle avoidance, 567
 - amnesia
 - anisomycin
 - cycloheximide
 - drug interactions
 - naloxone
 - passive avoidance
- Sidman avoidance schedule, 145
 - d-amphetamine
 - bin analysis
 - inter-response time
 - monkeys
- Simple carbohydrate comparisons, 681
 - hypocaloric diets
 - insulin receptors
 - obesity
- Simultaneous brightness discrimination, 939
 - d-amphetamine
 - two stage administration
- Single-trial, 1101
 - conditioned place preference
 - drug reinforcement
 - morphine
- Single unit activity, 607
 - ethanol effects
 - somatosensory cortex
- Sleep time, 333
 - circadian rhythm
 - sedation hypnosis
 - strain differences
- Smoking topography, 1245
 - carbon monoxide exposure
 - filter vent blocking
 - human studies
 - tobacco
- Snails, 1201
 - analgesia
 - classical conditioning
 - environmental specific cues
 - habituation
 - morphine
 - stress
 - tolerance
- Social isolation, 41
 - immobilization, acute
 - neurobiological responses
- Social stress, 449
 - drinking
 - hamsters
 - high-calorie fluids
 - reproduction
- Sodium pentobarbital, 35
 - classical conditioning
 - cross tolerance
 - ethanol
- Sodium valproate, 747
 - chlordiazepoxide
 - spatial behavior
- Somatosensory cortex, 607
 - ethanol effects
 - single unit activity
- Spatial behavior, 747
 - chlordiazepoxide
 - sodium valproate
- Spatial memory, 521
 - BW813U
 - choline acetyltransferase (ChAT)
 - inhibitor
 - radial maze performance
- Spinal motoneurons, 89
 - cannabidiol
 - cats
 - electrophysiological properties
 - synaptic effects
- Spontaneous chewing movements, 897
 - acute administration
 - antipsychotic drugs
 - chronic administration
 - tardive dyskinesia
- Step through latencies, 979
 - exponential data analysis
 - passive avoidance
- Stereoisomers, 375
 - fixed ratio/fixed interval schedule
 - locomotor activity
 - pentobarbital
 - secobarbital
 - variable interval schedule
- Stereotypy
 - alpha₂-adrenergic antagonists, 155
 - amphetamine, 155
 - atropine, 985
 - clonidine, 985
 - drug interactions, 985
 - hotplate test, 933
 - in vivo, 155
 - locomotor activity, 155, 985
 - pemoline, 933
 - self-injurious behavior, 933
- Stereotypy, apomorphine-induced, 1279
 - cyclo(leucyl-glycyl) (cLG)
 - dopamine receptors
- haloperidol
- supersensitivity
- Steroidogenesis, 753
 - adrenal cortex
 - adrenocorticotrophin 1–24 (ACTH (1–24))
 - corticosterone synthesis
- Stimulants, 277
 - investigatory behavior
 - locomotor activity
 - multivariate assessment
- Stimulation-produced analgesia, 533
 - antinociceptive system
 - morphine
 - opiate tolerance
- Stimulus control, 227
 - lysergic acid diethylamide (LSD)
 - pizotyline
 - verapamil
- Stimulus properties
 - dose-dependent effects, 1207
 - drug discrimination, 785, 1207
 - metazocine, 785
 - 5-methoxy-N,N-dimethyltryptamine (5-OMe DMT), 1207
 - monkeys, 785
 - self-administration, 785
 - serotonin antagonists, 1207
- Strain differences
 - caffeine, 1271
 - circadian rhythm, 333
 - hypertension, 317
 - lesions, substantia nigra, 317
 - locomotor activity, 1271
 - open field, 317
 - sedation hypnosis, 333
 - sleep time, 333
 - striatal dopamine content, 317
 - theophylline, 1271
- Stress
 - adjunctive consumption, 1163
 - alcohol, 1163
 - analgesia, 1201
 - bupirone, 457
 - p-chlorophenylalanine (PCPA), 415
 - classical conditioning, 1201
 - corticosterone secretion, 457
 - drinking, 1163
 - environmental specific cues, 1201
 - extinction, 1163
 - habituation, 1201
 - lithium, 1163
 - morphine, 1201
 - prolactin secretion, 457
 - shock, 1163
 - shock, uncontrollable, 415
 - snails, 1201
 - tolerance, 1201
- Stress-induced analgesia, 181
 - classical conditioning
 - tail flick
- Striatal dopamine content, 317
 - hypertension
 - lesions, substantia nigra
 - open field
 - strain differences
- Striatal dopamine system, 865
 - DOPAC/DA ratio
 - dopamine release
 - unilateral barpressing
- Striatum, 1095
 - dopamine metabolism

- feeding behavior
- ingestion
- nucleus accumbens
- Subdienecephalic rat brain, 347
 - prostaglandin
 - pyrexia
- Subjective ratings, 659
 - human studies
 - marijuana smoking
 - tobacco smoking
- Substance P, 469
 - avoidance learning
 - inhibitory avoidance
- Sucrose, 1001
 - drinking
 - morphine
 - naloxone-precipitated withdrawal
 - physical dependence
- Sucrose concentration, 219
 - anhedonia
 - licking
 - pimozide
- Supersensitivity, 1279
 - cyclo(leucyl-glycyl) (cLG)
 - dopamine receptors
 - haloperidol
 - stereotypy, apomorphine-induced
- Sympathomimetics, 233
 - locomotor behavior
 - opiates
 - psychostimulants
- Synaptic effects, 89
 - cannabidiol
 - cats
 - electrophysiological properties
 - spinal motoneurons

- Tail flick, 181
 - classical conditioning
 - stress-induced analgesia
- Tamoxifen, 497
 - cocaine
 - haloperidol
 - self-administration
 - sex differences
- Tardive dyskinesia
 - acute administration, 897
 - antipsychotic drugs, 897
 - cholinesterase inhibitors, 1217
 - chronic administration, 897
 - perioral behaviors, 1217
 - physostigmine, 1217
 - spontaneous chewing movements, 897
- Temporal analysis, 995
 - conditioned taste aversion
 - duration of action
 - tryptamine
- Testosterone, 823
 - chicks
 - memory
- Δ^9 -Tetrahydrocannabinol (Δ^9 -THC), 827
 - in vitro
 - metabolic interactions
 - phencyclidine (PCP)
 - Ca²⁺-precipitated liver microsomes
- Tetralin analogues, 135
 - drug discrimination
 - 8-hydroxy-2-(di-n-propylamino)
 - tetralin (8-OH DPAT)
 - ketanserin pretreatment
- Tetrodotoxin, 857
 - lordosis disruption
 - midbrain infusions
 - procaine
- Theobromine, 769
 - adenosine receptors
 - hypothermia
 - inbred strains
 - locomotor activity
 - methylxanthines
- Theophylline, 1271
 - caffeine
 - locomotor activity
 - strain differences
- Thermic response shifts, 83
 - conditioned hyperactivity hypothesis
 - drug interactions
- Thermoregulation
 - Ca²⁺-ATPase activity, 549
 - calcium channel antagonists, 555
 - cholinesterase inhibition, 1071
 - clinical chemistry, 1071
 - dihydropyridine receptors, 549
 - drug interactions, 555
 - heat, 1071
 - hyperthermia, 555
 - pyridostigmine, 1071
- 5-Thioglucose, 59
 - 2-deoxyglucose
 - feeding behavior
 - hyperphagia
 - lateral hypothalamus
 - ventromedial hypothalamus
- Time-dependent modulation, 919
 - amphetamine-induced hyperactivity
 - estrogen
- Time estimation, 1185
 - D₂ receptors
 - dopamine
 - internal clock speed
 - neuroleptics
- Timeout from avoidance, 439
 - CGS 8216
 - drug interactions
 - ethanol
 - naltrexone
 - shock avoidance
- Tizanidine, 835
 - antinociception
 - drug comparisons
 - drug interactions
 - morphine
 - tolerance
- Tobacco, 1245
 - carbon monoxide exposure
 - filter vent blocking
 - human studies
 - smoking topography
- Tobacco deprivation, 879
 - electroencephalographic effects
 - human studies, smokers
 - nicotine gum
- Tobacco smoking, 659
 - human studies
 - marijuana smoking
 - subjective ratings
- Tolerance
 - acoustic startle, 1175
 - acute administration, 1195
 - age differences, 359
 - aggression, 1195
 - ambient temperature, 667
 - amphetamine, 1175
 - analgesia, 1201
 - antinociception, 835
 - benzodiazepines, 1237
 - body temperature, 1293
 - l-cathinone, 13
 - cats, 359
 - chickens, 1237
 - chlordiazepoxide, 1237
 - chronic administration, 13, 667, 1195
 - chronic infusion, 483
 - classical conditioning, 1201
 - cocaine, 1175
 - cross-tolerance, 1175
 - diisopropylfluorophosphate (DFP), 1293
 - drug administration, 13
 - drug comparisons, 835
 - drug interactions, 835
 - environmental specific cues, 1201
 - ethanol, 667
 - habituation, 1175, 1201
 - heart rate, 1293
 - hypothermia, ethanol-induced, 667
 - intrathecal injection, 483
 - locomotor activity, 1293
 - magnesium, 1195
 - morphine, 835, 1201
 - muscarinic receptors, 1293
 - phencyclidine (PCP), 1175
 - phencyclidine (PCP) metabolites, 359
 - ³H-quinuclidinyl benzilate (³H-QNB)
 - binding, 1293
 - respiration rate, 1293
 - sensitization, 1175
 - snails, 1201
 - stress, 1201
 - tizanidine, 835
 - tonic immobility, 1237
- Tonic immobility
 - benzodiazepines, 1237
 - chickens, 1237
 - chlordiazepoxide, 1237
 - hippocampal 5-HT activity, 781
 - rabbits, 781
 - tolerance, 1237
- Tripelennamine, 629
 - brain stimulation
 - drug interactions
 - nalbuphine
 - reward threshold
- Tryptamine, 995
 - conditioned taste aversion
 - duration of action
 - temporal analysis
- L-Tryptophan, 849
 - amphetamine self-administration
- Two-bottle choice paradigm, 431
 - benzodiazepines
 - conditioned taste aversion
 - drinking
 - polydipsia
- Two stage administration, 939
 - d-amphetamine
 - simultaneous brightness discrimination
- Type 2 receptors, 1145
 - benzodiazepines
 - convulsions
 - hyperactivity
 - neonates
- Tyrosine hydroxylase activity, 763
 - adrenergic receptors

- dopamine receptors
- marijuana
- perinatal exposure
- L-Tyrosine, 1027
 - amphetamine self-administration
 - brain catecholamines
- Ulcer proliferation, 1083
 - restraint stress
 - voluntary ethanol consumption
- Unilateral barpressing, 865
 - DOPAC/DA ratio
 - dopamine release
 - striatal dopamine system
- Unrestrained animals, 487
 - intracerebral cannula
 - rodents, small
- Valproic acid, 929
 - delayed-matching-to-sample
 - drug interactions
 - phenobarbital
 - phenytoin
 - pigeons
- Variable interval schedule
 - drug interactions, 149
 - fixed ratio/fixed interval schedule, 375
 - imipramine, 149
 - locomotor activity, 375
 - methadone, 149
 - pentobarbital, 375
 - pigeons, 149
 - secobarbital, 375
 - stereoisomers, 375
- Vasopressin
 - barrel rotation, 583
 - consolidation, 1125
 - lesions, kainic acid, 583
 - memory effects, time related, 1125
- nicotine, 583
 - passive avoidance behavior, 1125
 - prostration, 583
 - retrieval, 1125
 - vasopressin analogues, 1125
 - vestibular cerebellum, 583
- Vasopressin analogues, 1125
 - consolidation
 - memory effects, time related
 - passive avoidance behavior
 - retrieval
 - vasopressin
- Vasopressin-like peptides, 797
 - ethanol tolerance
 - limbic structures
 - serotonin synthesis
- Ventral tegmental area, 959
 - circling, opiate-induced
 - dopaminergic system
 - opiate receptors
- Ventromedial hypothalamus, 59
 - 2-deoxy-D-glucose
 - feeding behavior
 - hyperphagia
 - lateral hypothalamus
- Verapamil, 227
 - lysergic acid diethylamide (LSD)
 - pizatyline
 - stimulus control
- Vestibular cerebellum, 583
 - barrel rotation
 - lesions, kainic acid
 - nicotine
 - prostration
 - vasopressin
- Voltammetric recording, 325
 - in vivo
 - nafion-coated electrodes
- Voluntary ethanol consumption, 1083
 - restraint stress
 - ulcer proliferation
- Water, 1159
 - adjunctive consumption
 - alcohol
 - drinking
 - extinction
 - lithium
- Water balance, 77
 - drinking
 - opioid agonists
- Water deprivation, 1153
 - 2-deoxy-D-glucose
 - glucoprivation
 - hypophagia
 - liquid diet
- Water maze, 141
 - brain iron-deficiency
 - learning
- Water reinforcement, 1231
 - anhedonia
 - haloperidol
 - partial reinforcement extinction effect
 - reward omission, periodic
- Withdrawal, precipitated, 1263
 - morphine
 - reinforcement threshold
 - response rate
 - self-stimulation
 - withdrawal, spontaneous
- Withdrawal, spontaneous, 1263
 - morphine
 - reinforcement threshold
 - response rate
 - self-stimulation
 - withdrawal, precipitated
- Working memory, 633
 - delayed response
 - discrimination
 - response bias
 - scopolamine

AUTHOR INDEX

- | | | | |
|--|--|---|--|
| <ul style="list-style-type: none"> Abed, W. T., 949 Abiru, T., 463 Abla, K. A., 1271 Abood, L. G., 583, 589 Addington, S., 989 Akiyoshi, J., 805 Allweis, C., 979 Alpern, H. P., 333, 1077 Alvarado, M. C., 487 Amalric, M., 233 Anderson, D., 415 Andersson, U., 897 Andrew, R. J., 823 Anisman, H., 29 Apfelbaum, M., 681, 913 Armstrong, D. E., 561 Aronstam, R. S., 985 Avery, D. D., 7 Ayhan, I. H., 215 Azar, A. P., 381 Baigts, F., 681 Balster, R. L., 785 Bapna, J. S., 59 | <ul style="list-style-type: none"> Bardo, M. T., 1101 Barnett, G., 365 Barrett, J., 1089 Barrett, J. E., 371 Bartles, R. R., 1153 Bassett, J. R., 753 Bayn, P., 681 Beaman, C. M., 697 Beaton, J. M., 1191 Beckstead, J. W., 1237 Benedikt, R. A., 889 Benedito, M. A. C., 223 Bengelloun, W. A., 903 Bennett, E. L., 487 Benowitz, N. L., 1181 Ben-Shahar, O., 939 Berge, O.-G., 883 Bergman, J., 973 Bethea, C. L., 457 Betoulle, D., 913 Birbeck, K.-A., 747 Blackburn, J. R., 1095 Blundell, J. E., 123 Bodnar, R. J., 171 | <ul style="list-style-type: none"> Bolger, G. T., 45, 51 Bolin, J., 1107 Bondesson, U., 897 Bowen, D. J., 1131 Bowman, R. E., 1117 Brady, J. V., 577 Bray, G. A., 733 Braz, S., 223 Breese, G. R., 63 Bridges, R. S., 1007 Brne, T., 1107 Brown, R., 107 Browne, R. G., 1051 Buscufusco, J. J., 985 Buchanan, G. D., 527 Buchanan, S. L., 423 Burks, T. F., 77 Burton, C. K., 599 Burton, M. J., 23, 711 Bushnell, P. J., 161 Callahan, M. F., 641 Cam, G. R., 753 Camarena, M. L., 1217 | <ul style="list-style-type: none"> Camp, C. H., 813, 1231 Cannon, D. J., 117 Cao, W., 769, 1271 Carney, J. M., 769, 1271 Carnoy, P., 503 Carr, G. D., 17 Carr, L. A., 763 Carson, J., 521 Castellano, C., 181 Chamberlain, J., 95 Chandra, D., 59 Chapin, J. K., 607 Chernichovsky, D., 979 Cho, C. H., 775 Church, W. H., 865 Chute, S., 129 Clark, W. G., 481 Cleary, J., 149 Coenen, A. M. L., 329 Coffey, P. J., 711 Collins, A. C., 1293 Cooper, S. J., 99, 341 Cordoba, F., 71 Coscina, D. V., 401 |
|--|--|---|--|

- Couch, L., 117
Crabbe, J. C., 289
Crawley, J. N., 45
Cunnane, S. C., 1285
- Dai, S., 1001
Dalton, J. C. H., 497
DaVanzo, J. P., 95
Dawson, R. G., 1089
de Belleruche, J. S., 943
Deckel, A. W., 297
DE Jong, W., 317
DeLeon-Jones, F. A., 1279
Deupree, D., 77
De Wied, D., 1125
D'Onofrio, G., 651
Duka, T., 595
Durel, L. A., 371
Durivage, M. E., 155
- Edwards, E., 415
Eldred, N. L., 449
El Mestikawy, S., 1
Enginar, N., 953
Ettenberg, A., 791, 813, 1231
Eury, S. E., 1131
Evans, K. R., 1149
Exley, R. J., 989
- Falcou, R., 913
Farabollini, F., 781
Fasmer, O. B., 883
Feldon, J., 939
Fibiger, H. C., 1095
Fields, J. Z., 1279
Filart, R., 381
File, S. E., 1145
Fishbein, W., 1253
Fishman, M. W., 577
Fletcher, P. J., 23, 995
Foltin, R. W., 577
Fowler, S. C., 219, 615, 791
Francesconi, R., 1071
Franklin, S. R., 925
Fudala, P. J., 1041
Fumeron, F., 681
Funahashi, M., 1035
Furukawa, T., 463
- Gaffori, O. J. W., 1125
Galizio, M., 439
Gallup, G. G., Jr., 1237
Garcia-Valdez, K., 1195
Gardiner, I. M., 943
Geis, L. S., 1027
Geyer, M. A., 277
Gianutsos, G., 129
Gibbs, M. E., 823
Giesecke, Jr., A. H., 481
Giuditta, A., 651
Glavin, G. B., 1083
Glennon, R. A., 135, 1207
Glick, S. D., 1021
Glick, Z., 491
Glowa, J. R., 973
Goeders, N. E., 191
Gonzalez, L. P., 1279
Gori, G. B., 1181
Gorzalka, B. B., 111
Gramling, S. E., 219, 615
Grassi, S., 583, 589
Grecksch, G., 1137
- Griffiths, R. R., 659
Grondin, L., 903
Grunberg, N. E., 1131
Güngör, M., 953
Gunne, L. M., 897
- Hahn, B., 29
Hall, A., 1083
Hamilton, M. H., 943
Hamon, M., 1
Hara, C., 757
Hardwick, W. C., 117
Harlan, R. E., 857
Hashimoto, H., 411
Hatipoğlu, I., 953
Hawkins, C., 1153
Heise, G. A., 633
Hempel, A. G., 989
Henault, M. A., 297
Henn, F. A., 415
Henningfield, J. E., 659, 879
Hepler, D. J., 293
Herberg, L. J., 943
Herning, R. I., 879
Hitunen, A. J., 393
Hines, G., 1159, 1163
Hirst, M., 543, 1201
Hizal, A., 953
Ho, I. K., 599
Hole, K., 883
Hollingsworth, E., 933
Hook, R., 843
Horrobin, D. F., 1285
Hoskins, B., 599
Howard-Butcher, S., 359
Hruby, V., 77
Hsiao, S., 77
Huang, Y.-S., 1285
Hubbard, R., 1071
Hughes, D., 521
Hunter, G. A., 697
Husain, S., 827
Huston, J. P., 469
Hydén, H., 651
- Ingram, D. K., 673
Iwamoto, E. T., 1041
Izenwasser, S. E., 1195
- Jacobson, W., 527
Jähkel, M., 41
Jakubovic, A., 1095
Järbe, T. U. C., 393
Jarvis, M. J., 727
Jhanwar-Uniyal, M., 381
Johansson, P., 897
Johnson, J., 415
Jones, B., 889
Jork, R., 1137
Justice, A., 263
Justice, J. B., Jr., 865
- Kalant, H., 667, 797
Kamachi, G. L., 59
Kameyama, T., 567, 835
Kamimura, H., 411
Kamiya, H., 463
Kantak, K. M., 1195
Kaplan, E., 843
Karas, C. A., 929
Karler, R., 89
Kastin, A. J., 757, 1303
- Katz, N. L., 1107
Kavaliers, M., 543, 1201
Kempf, E., 1211
Khanna, J. M., 667
Kimura, H., 1035
Kinsley, C. H., 1007
Kirkham, T. C., 123, 341
Klimek, V., 329
Knudson, K., 1223
Kohda, H., 1035
Kokkinidis, L., 1175
Koo, M. W. L., 775
Koob, G. F., 233
Kornetsky, C., 629
Koyuncuoğlu, H., 953
Kozawa, T., 567
Kozlowski, M. R., 1051
Kramer, E., 171
Krantz, D. S., 371
Ktorza, A., 681
Kulkosky, P. J., 1067
- LaCerra, M. M., 791
Ladowsky, R. L., 269
Lakhdar-Ghazal, N., 903
Lamé, M. W., 827
Lander, N., 393
Lasoñ, W., 967
Le, A. D., 667
Leccese, A. P., 849
Lee, J. M., 1279
Leibowitz, S. F., 381, 1223
Lerer, B. E., 293
Leung, C. M. K., 1001
Leva, N., 1071
Levin, E. D., 1117
Levine, M. S., 359
Li, T.-K., 1013
Liao, R.-M., 615
Licko, V., 365
Lieber, P., 1279
Lipton, J. M., 481
Liu, W.-F., 1191
Livesey, D. J., 1089
Livesey, P. J., 1089
Livovsky, M., 7
Lodi, L., 781
Logan, L., 769
LoLordo, V. M., 561
Lorens, S. A., 457
Lukas, S. E., 889
Lumeng, L., 1013
Lupien, J. R., 733
Lupo, C., 781
Luttinger, D., 155
Lynch, C. J., 1181
Lyness, W. H., 849, 1027
- McCallister, L. W., 481
McConnaughey, M. M., 95
McCown, T. J., 63
McEvoy, P. M., 35
McIntyre, T. D., 333, 1077
McKinney, J., 1153
McMillan, D. E., 117, 209
- Maier, D. M., 703
Maiti, A., 583, 589
Majeed, N. H., 967
Malin, D. H., 989
Martin, P., 1
Martin, W. R., 843
- Masten, V. L., 277
Mastropaolo, J., 201
Masur, J., 739
Matsuno, K., 835
Matthew, C., 1071
Matthies, H., 1137
Mattingly, B. A., 693
May, F. L., 785
Mechoulam, R., 393
Meck, W. H., 1185
Mehta, A. K., 1059
Mendelson, J. H., 889
Mendelson, S. D., 111
Menna, T., 651
Meyerson, L. R., 1279
Michael, R. P., 919, 1263
Mintz, M., 1307
Moerschbaecher, J. M., 201
Mogilnicka, E., 329, 743
Mokler, D. J., 717
Molloy, A. G., 249, 985
Monaghan, E. P., 573
Montgomery, A. M. J., 23, 711
Marato, G. S., 739
Mori, T., 411
Morozova, A. S., 533
Mosberg, H. I., 77
Moss, D. E., 1217
Mostofsky, D. I., 141
Mueller, D., 325, 933
Muir, J. L., 107
Munoz-Blanco, J., 71
- Nabeshima, T., 567, 835
Nader, M., 149
Nagayama, H., 805
Nakajima, T., 411
Nakao, J., 411
Napier, T. C., 63
Nassif-Caudarella, S., 1211
Neill, D. B., 865
Neisewander, J. L., 1101
Nemeth-Coslett, R., 659
Ng, K. T., 823
Nichols, N. F., 255
Nobrega, J. N., 401
Noto, T., 411
Numan, R., 1111
- O'Boyle, K. M., 249
Oehler, J., 41
Ogle, C. W., 775, 1001
O'Keefe, M. K., 659
Oliverio, A., 181
Olorundare, O. E., 347, 353
Olton, D., 521
Ono, N., 463
Oshiro, A., 491
Ossenkopp, K.-P., 269
- Palaoglu, Ö., 215
Papadakos, P., 1223
Papasava, C., 623
Papasava, M., 623
Parker, K. M., 1271
Patterson, T. A., 487
Paul, S. M., 45
Pavone, F., 181
Pease, V., 1071
Perone, M., 439
Perrone Capano, C., 651
Peters, D. A. V., 873

- Pettit, H., 933
 Pfaff, D. W., 857
 Pfister, H. P., 107
 Phillips, A. G., 1095
 Picker, M., 929
 Pickworth, W. B., 879
 Pillai, N. P., 549, 555
 Pires, M. L. N., 739
 Pisa, M., 689
 Pohorecky, L. A., 703
 Poling, A., 929
 Popplewell, D. A., 711
 Porreca, F., 77
 Poshivalov, V. P., 515
 Post, C., 883
 Powell, D. A., 423
 Przewlocka, B., 329, 967
 Przewlocki, R., 967
 Pugh, M. T., 249

 Rabillon, B., 681
 Rafferty, M. F., 45, 51
 Rager, D. R., 1237
 Raigoza, V. P., 1067
 Randich, A., 641
 Ravard, S., 503
 Reader, T. A., 903
 Rech, R. H., 717
 Reichert-Hunter, G. L., 697
 Reid, L. D., 697
 Rennert, O. M., 769, 1271
 Reyes, E., 1217
 Rhea, K., 1153
 Rhodes, D. H., 1153
 Rice, K. C., 51
 Rigby, P., 673
 Riley, E. P., 1021
 Ritzmann, R. F., 1279
 Rizkalla, S. W., 681
 Roache, J. D., 431
 Roberts, D. C. S., 497
 Robinson, R. G., 263
 Rockman, G. E., 1083
 Rodriguez, L. A., 1217
 Rosecrans, J. A., 1207
 Rosenweig, M. R., 487
 Ross, D. H., 549, 555
 Rothfeld, J. M., 857

 Rudy, T. A., 347, 353
 Rush, D. K., 145
 Russo, P. V., 277

 Sabol, K. E., 865
 Saito, R., 463
 Sakai, D. H., 487
 Sanberg, P. R., 231, 297
 Sanchez, M. R., 1067
 Sanger, D. J., 537
 Schaefer, G. J., 1263
 Schechter, M. D., 13, 337
 Schlemmer, R. F., Jr., 1107
 Schmidt, J., 41
 Schnur, P., 1067
 Schreur, P. J. K. D., 255
 Scoles, M. T., 1169
 Seale, T. W., 769, 1271
 Sethy, V. H., 925
 Seyrig, J. A., 913
 Shahid Salles, K., 583, 589
 Sherman, L. C., 717
 Shikata, I., 1035
 Shiromani, P. J., 1253
 Shivers, B. D., 857
 Shor-Posner, G., 381
 Shulz, D., 979
 Siegel, S., 1169
 Simon, P., 1, 503
 Singer, G., 623
 Skolnick, P., 45, 51
 Slifer, B. L., 785
 Sloan, J. W., 843
 Smith, D. G., 849, 1027
 Smith, F. L., 849, 1027
 Smith, J. E., 191
 Smolen, A., 1293
 Smolen, T. N., 1293
 Sod-Moriah, U., 491
 Sorensen, S. M., 607
 Soubrie, Ph., 1, 503
 Souza, M. L. O., 739
 Spangler, E. L., 673
 Speisky, M. B., 797
 Spencer, B. A., 439
 Spencer, R. L., 77
 Sperber, E. S., 171
 Spickett, T. J., 1089

 Spielmann, D., 681
 Spoerlein, M. T., 959
 Stähle, L., 473
 Steece, K. A., 1279
 Stephens, D. N., 595
 Stevens, C. W., 483
 Stitzer, M. L., 1245
 Stoudt, K. W., 717
 Sugimoto, A., 835
 Sunal, R., 511
 Sutherland, C., 269
 Sweeney, J., 521
 Swerdlow, N. R., 233
 Szechtman, H., 689
 Szwczak, M. R., 959

 Talanian, R. V., 697
 Tang, A. H., 925
 Taukulis, H. K., 83
 Thiebot, M. H., 1
 Thompson, D. M., 185, 201
 Thompson, T., 149, 365
 Ticku, M. K., 1059
 Tobo, M., 805
 Tomaz, C., 469
 Tomer, R., 1307
 Tosiatti, C., 651
 Treit, D., 561
 Troncone, L. R. P., 223
 Tufik, S., 223
 Turano, P., 415
 Turkanis, S. A., 89

 Ungerstedt, U., 473
 Unterwald, E. M., 629
 Urban, J. H., 457

 Vaccarino, F. J., 233, 1149
 Valdman, A. V., 515
 Van de Kar, L. D., 457
 van den Buuse, M., 317
 van Luitelaar, E. L. J. M., 329
 Veeraragavan, K., 59
 Veldhuis, H. D., 317
 Vellely, L., 1211
 Versteeg, D. H. G., 317
 Vickers, G. J., 497

 Vinick, F. J., 1051
 Viscardi, A. P., 633

 Waddington, J. L., 249
 Walters, D. E., 763
 Ward, I. L., 573
 Ward, O. B., 573
 Wash, C., 843
 Watson, P. J., 1153
 Weiner, I., 939
 Weiss, G. F., 1223
 Weissman, B. A., 51
 Wemerman, B., 503
 Wenger, G. R., 375
 Wenger, J. R., 35
 Wenk, G., 521
 Wessinger, W. D., 209
 West, C. H. K., 919
 West, R. J., 727
 White, N. M., 17
 Wilkinson, M., 527
 Wilks, L. J., 1145
 Willner, P., 747
 Winsauer, P. J., 185, 201
 Winter, J. C., 227
 Wise, D. A., 449
 Woods, S. C., 35
 Woodward, D. J., 607

 Yaksh, T. L., 483
 Yamada, S., 835
 Yehuda, S., 141
 Yerbury, R. E., 99
 Yingling, J. E., 1245
 Youdim, M. E. H., 141
 Young, J., 1071
 Young, R., 1207
 Younglai, F. V., 527
 Yu, D. S. L., 849, 1027
 Yusta, B., 71

 Zabik, J. E., 431
 Zacharko, R. M., 29
 Zacny, J. P., 1245
 Zadina, J. E., 1303
 Zimmerberg, B., 1021
 Zvartau, E. E., 533

CONTENTS

Articles

- The lesion of serotonergic neurons does not prevent antidepressant-induced reversal of escape failures produced by inescapable shocks in rats.**
 SOUBRIE, P., P. MARTIN, S. EL MESTIKAWY, M. H. THIEBOT, P. SIMON
 and M. HAMON 1
- Peripheral injections of bombesin and cholecystokinin affect dietary self-selection in rats.**
 AVERY, D. D. and M. LIVOSKY 7
- Induction of and recovery from tolerance to the discriminative stimulus properties of *l*-cathinone.**
 SCHECHTER, M. D. 13
- Contributions of dopamine terminal areas to amphetamine-induced anorexia and adipisia.**
 CARR, G. D. and N. M. WHITE 17
- Behavioural and pharmacological investigations of 5-HT hypophagia and hyperdipsia.**
 MONTGOMERY, A. M. J., P. J. FLETCHER and M. J. BURTON 23
- Alterations of amphetamine elicited perseveration and locomotor excitation following acute and repeated stressor application.**
 HAHN, B., R. M. ZACHARKO and H. ANISMAN 29
- Sodium pentobarbital-induced cross-tolerance to ethanol is learned in the rat.**
 WENGER, J. R., P. M. McEVOY and S. C. WOODS 35
- Altered neurobiological responses to acute immobilization in social-isolated mice.**
 OEHLER, J., M. JÄHKEL and J. SCHMIDT 41
- Effects of calcium antagonists on phencyclidine behaviors.**
 BOLGER, G. T., M. F. RAFFERTY, J. N. CRAWLEY, S. M. PAUL and
 P. SKOLNICK 45
- Acylation of phencyclidines irreversibly enhance brain calcium antagonist binding.**
 BOLGER, G. T., M. F. RAFFERTY, B. A. WEISSMAN, K. C. RICE and
 P. SKOLNICK 51
- Antagonism of acute feeding response to 2-deoxyglucose and 5-thiogluucose by GABA antagonists: The relative role of ventromedial and lateral hypothalamus.**
 LENIN KAMATCHI, G., K. VEERARAGAVAN, DINESH CHANDRA and
 J. S. BAPNA 59
- Effects of chronic electrode implantation on dopaminergic neurons *in vivo*.**
 McCOWN, T. J., T. C. NAPIER and G. R. BREESE 63

| | |
|---|-----|
| Differential distribution of neurotransmitter amino acids from the limbic system of aggressive and non-aggressive bull strains. | |
| MUÑOZ-BLANCO, J., B. YUSTA and F. CORDOBA | 71 |
| Centrally-administered opioid selective agonists inhibit drinking in the rat. | |
| SPENCER, R. L., D. DEUPREE, S. HSIAO, H. I. MOSBERG, V. HRUBY, T. F. BURKS and F. PORRECA | 77 |
| Conditional shifts in thermic responses to sequentially paired drugs and the "conditional hyperactivity" hypothesis. | |
| TAUKULIS, H. K. | 83 |
| Cannabidiol-caused depression of spinal motoneuron responses in cats. | |
| TURKANIS, S. A. and R. KARLER | 89 |
| Influence of environment on GABA receptors in muricidal rats. | |
| DAVANZO, J. P., J. CHAMBERLAIN and M. M. McCONNAUGHEY | 95 |
| Midazolam-induced hyperphagia and FG 7142-induced anorexia: Behavioural characteristics in the rat. | |
| COOPER, S. J. and R. E. YERBURY | 99 |
| A possible role for oxytocin in the response to a psychological stressor. | |
| MUIR, J. L., R. BROWN and H. P. PFISTER | 107 |
| Harmine reverses the inhibition of lordosis by the 5-HT₂ antagonists pirenperone and ketanserin in the female rat. | |
| MENDELSON, S. D. and B. B. GORZALKA | 111 |
| Relationship of plasma phencyclidine levels to phencyclidine discrimination in the pigeon. | |
| McMILLAN, D. E., W. C. HARDWICK, D. J. CANNON and L. COUCH | 117 |
| Effect of naloxone and naltrexone on the development of satiation measured in the runway: Comparisons with d-amphetamine and d-fenfluramine. | |
| KIRKHAM, T. C. and J. E. BLUNDELL | 123 |
| Pharmacological changes induced by repeated exposure to phenylethylamine. | |
| GIANUTSOS, G. and S. CHUTE | 129 |
| Discriminative stimulus properties of the 5-HT_{1A} agonist 8-hydroxy-2-(di-<i>n</i>-propylamino)tetralin (8-OH DPAT). | |
| GLENNON, R. A. | 135 |
| Brain iron-deficiency causes reduced learning capacity in rats. | |
| YEHUDA, S., M. E. H. YODIM and D. I. MOSTOFKY | 141 |
| Shuttlebox Sidman avoidance in rhesus monkeys: Day of week and amphetamine effects. | |
| RUSH, D. K. | 145 |
| Effects of imipramine on responding reduced by methadone. | |
| CLEARY, J., M. NADER and T. THOMPSON | 149 |
| Alpha₂-adrenergic antagonists effect on amphetamine-induced behaviors. | |
| LUTTINGER, D. and M. E. DURIVAGE | 155 |
| Differential effects of amphetamine and related compounds on locomotor activity and metabolic rate in mice. | |
| BUSHNELL, P. J. | 161 |

VOLUME INDEX

| | |
|--|-----|
| Effects of muscarinic receptor antagonism upon two forms of stress-induced analgesia. | |
| SPERBER, E. S., E. KRAMER and R. J. BODNAR | 171 |
| Transfer of conditioning of stress-induced analgesia. | |
| OLIVERIO, A., C. CASTELLANO and F. PAVONE | 181 |
| Nicotine can attenuate the disruptive effects of phencyclidine on repeated acquisition in monkeys. | |
| THOMPSON, D. M. and P. J. WINSAUER | 185 |
| Reinforcing properties of cocaine in the medial prefrontal cortex: Primary action on presynaptic dopaminergic terminals. | |
| GOEDERS, N. E. and J. E. SMITH | 191 |
| Repeated acquisition and delayed performance as a baseline to assess drug effects on retention in monkeys. | |
| THOMPSON, D. M., J. MASTROPAOLO, P. J. WINSAUER and J. M. MOERSCHBAECHER | 201 |
| Brief Communications | |
| Quantitative analysis of naloxone antagonism of the discriminative stimulus properties of morphine in the pigeon. | |
| WESSINGER, W. D. and D. E. McMILLAN | 209 |
| The possible role of benzodiazepine receptors in morphine analgesia. | |
| PALAOĞLU, Ö. and I. H. AYHAN | 215 |
| Some effects of pimozide and of shifts in sucrose concentration on lick rate, duration, and interlick interval. | |
| GRAMLING, S. E. and S. C. FOWLER | 219 |
| REM sleep deprivation induces a decrease in norepinephrine-stimulated ³H-cyclic AMP accumulation in slices from rat brain. | |
| TRONCONE, L. R. P., S. BRAZ, M. A. C. BENEDITO and S. TUFİK | 223 |
| Verapamil does not antagonize LSD-induced stimulus control. | |
| WINTER, J. C. | 227 |
| Meeting Report | |
| Proceedings of a Satellite Symposium to the 15th Annual Meeting of the Society for Neuroscience | 229 |
| Introduction | |
| Locomotor behavior: Neuropharmacological substrates of motor activation. | |
| SANBERG, P. R. | 231 |
| The neural substrates for the motor-activating properties of psychostimulants: A review of recent findings. | |
| SWERDLOW, N. R., F. J. VACCARINO, M. AMALRIC and G. F. KOOB ... | 233 |

| | |
|---|-----|
| Locomotor behaviors in response to new selective D-1 and D-2 dopamine receptor agonists, and the influence of selective antagonists. | |
| MOLLOY, A. G., K. M. O'BOYLE, M. T. PUGH and J. L. WADDINGTON | 249 |
| Two automated locomotor activity tests for dopamine autoreceptor agonists. | |
| SCHREUR, P. J. K. D. and N. F. NICHOLS | 255 |
| Mechanisms of lateralized hyperactivity following focal brain injury in the rat. | |
| ROBINSON, R. G. and A. JUSTICE | 263 |
| Motor activity changes and conditioned taste aversions induced by administration of scopolamine in rats: Role of the area postrema. | |
| OSSENKOPP, K.-P., C. SUTHERLAND and R. L. LADOWSKY | 269 |
| Multivariate assessment of locomotor behavior: Pharmacological and behavioral analyses. | |
| GEYER, M. A., P. V. RUSSO and V. L. MASTEN | 277 |
| Genetic differences in locomotor activation in mice. | |
| CRABBE, J. C. | 289 |
| The effect of magnocellular basal forebrain lesions on circadian locomotor activity in the rat. | |
| HEPLER, D. J. and B. E. LERER | 293 |
| Locomotor hyperactivity: | |
| Effects of multiple striatal transplants in an animal model of Huntington's disease. | |
| SANBERG, P. R., M. A. HENAULT and A. W. DECKEL | 297 |
| Ninety-Fourth Annual Convention of the American Psychological Association | |
| Abstracts | 301 |
| Author's Correction | 315 |

CONTENTS

Articles

- Substantia nigra lesions attenuate the development of hypertension and behavioural hyperreactivity in Spontaneously Hypertensive Rats.**
 VAN DEN BUUSE, M., H. D. VELDHUIS, D. H. G. VERSTEEG and
 W. DE JONG 317
- In vivo* voltammetric recording with nafion-coated carbon paste electrodes:
 Additional evidence that AA release is monitored.**
 MUELLER, K. 325
- Effects of REM sleep deprivation on central α_1 - and β -adrenoceptors in rat brain.**
 MOGILNICA, E., B. PRZEWŁOCKA, E. L. J. M. VAN LUIJTELAAR,
 V. KLIMEK and A. M. L. COENEN 329
- Sedative-hypnotic anomalies related to dose of pentobarbital in long-sleep and short-sleep
 selectively-bred mice.**
 ALPERN, H. P. and T. D. MCINTYRE 333
- Dopaminergic mediation of a behavioral effect of *l*-cathinone.**
 SCHECHTER, M. D. 337
- CGS 8216, a novel anorectic agent, selectively reduces saccharin solution consumption in the rat.**
 KIRKHAM, T. C. and S. J. COOPER 341
- Examination of the subdienecephalic rat brain for sites mediating PGE₁-induced pyrexia.**
 OLORUNDARE, O. E. and T. A. RUDY 347
- Studies on the pyrexia effect of PGE₁ injected into the region of the cochlear nuclei.**
 OLORUNDARE, O. E. and T. A. RUDY 353
- Behavioral effects of phencyclidine and some of its metabolites in developing cats.**
 LEVINE, M. S. and S. HOWARD-BUTCHER 359
- Asynchronies of diphenhydramine plasma-performance relationships.**
 LICKO, V., T. THOMPSON and G. BARNETT 365
- The antianxiety effect of beta-blockers on punished responding.**
 DUREL, L. A., D. S. KRANTZ and J. E. BARRETT 371
- Behavioral effects of the isomers of pentobarbital and secobarbital in mice and rats.**
 WENGER, G. R. 375
- Destruction of noradrenergic innervation to the paraventricular nucleus: Deficits in food intake,
 macronutrient selection and compensatory eating after food deprivation.**
 SHOR-POSNER, G., A. P. AZAR, M. JHANWAR-UNIYAL, R. FILART and
 S. F. LEIBOWITZ 381
- Cannabimimetic activity (Δ^1 -THC cue) of cannabidiol monomethyl ether and two stereoisomeric
 hexahydrocannabinols in rats and pigeons.**
 JARBE, T. U. C., A. J. HILTUNEN, N. LANDER and R. MECHOULAM ... 393

| | |
|---|-----|
| Dopamine-norepinephrine interactions in the development of hyperphagia and obesity following medial hypothalamic lesions. | |
| NOBREGA, J. N. and D. V. COSCINA | 401 |
| The effect of L-erythro-dihydroxyphenylserine injected into the lateral ventricle and the hypothalamus on the locomotor activity. | |
| NOTO, T., H. HASHIMOTO, J. NAKAO, H. KAMIMURA, T. MORI and T. NAKAJIMA | 411 |
| Neurochemical and behavioral consequences of mild, uncontrollable shock: Effects of PCPA. | |
| EDWARDS, E., J. JOHNSON, D. ANDERSON, P. TURANO and F. A. HENN | 415 |
| Autonomic changes elicited by chemical stimulation of mediodorsal nucleus of the thalamus. | |
| POWELL, D. A. and S. L. BUCHANAN | 423 |
| Effects of benzodiazepines on taste aversions in a two-bottle choice paradigm. | |
| ROACHE, J. D. and J. E. ZABIK | 431 |
| Variable interval schedules of timeout from avoidance: Effects of ethanol, naltrexone, and CGS 8216. | |
| GALIZIO, M., M. PERONE and B. A. SPENCER | 439 |
| Maternal social stress disrupts reproduction of hamsters drinking high-calorie fluids. | |
| WISE, D. A. and N. L. ELDRED | 449 |
| Effect of the anxiolytic drug buspirone on prolactin and corticosterone secretion in stressed and unstressed rats. | |
| URBAN, J. H., L. D. VAN DE KAR, S. A. LORENS and C. L. BETHEA ... | 457 |
| Possible involvement of prostaglandins in cataleptic behavior in rats. | |
| ONO, N., R. SAITO, T. ABIRU, H. KAMIYA and T. FURUKAWA | 463 |
| Facilitation of conditioned inhibitory avoidance by post-trial peripheral injection of substance P. | |
| TOMAS, C. and J. P. HUSTON | 469 |
| Effects of neuroleptic drugs on the inhibition of exploratory behaviour induced by a low dose of apomorphine: Implications for the identity of dopamine receptors. | |
| STÅHLE, L. and U. UNGERSTEDT | 473 |
| Brief Communications | |
| The rabbit ear-withdrawal test: A new analgesiometric procedure. | |
| McCALLISTER, L. W., J. M. LIPTON, A. H. GIESECKE, JR. and W. G. CLARK | 481 |
| Simple catheter preparation for permitting bolus intrathecal administration during chronic intrathecal infusion. | |
| YAKSH, T. L. and C. W. STEVENS | 483 |
| An economically constructed and durable intracerebral cannula system for small rodents. | |
| PATTERSON, T. A., M. C. ALVARADO, D. H. SAKAI, M. R. ROSENZWEIG and E. L. BENNETT | 487 |
| Effects of acarbose in rats are influenced by the type of dietary starch. | |
| GLICK, Z., A. OSHIRO and U. SOD-MORIAH | 491 |

CONTENTS

Articles

- Increased self-administration of cocaine following haloperidol:
Sex-dependent effects of the antiestrogen tamoxifen.**
DALTON, J. C. H., G. J. VICKERS and D. C. S. ROBERTS 497
- Behavioral deficits induced by low doses of apomorphine in rats: Evidence for a motivational and cognitive dysfunction which discriminates among neuroleptic drugs.**
CARNOY, P., S. RAVARD, B. WEMERMAN, Ph. SOUBRIE and P. SIMON 503
- Influence of naloxone on H₂-receptor blocker drugs effects in the "behavioral despair" test.**
SUNAL, R. 511
- Pharmacological analysis of antidepressant drug effects.**
VALDMAN, A. V. and V. P. POSHIVALOV 515
- Cholinergic function and memory:
Extensive inhibition of choline acetyltransferase fails to impair radial maze performance in rats.**
WENK, G., J. SWEENEY, D. HUGHEY, J. CARSON and D. OLTON 521
- Brain opioid receptors in the hibernating bat, *Myotis lucifugus*:
Modification by low temperature and comparison with rat, mouse and hamster.**
WILKINSON, M., G. D. BUCHANAN, W. JACOBSON and E. V. YOUNGLAI 527
- Stimulation-produced analgesia under repeated morphine treatment in rats.**
MOROZOVA, A. S. and E. E. ZVARTAU 533
- Investigation of the actions of the benzodiazepine antagonists Ro 15-1788 and CGS 8216 using the schedule-controlled behavior of rats.**
SANGER, D. J. 537
- Food hoarding and ingestion in the deer mouse, *Peromyscus maniculatus*:
Selective responses to mu and kappa opiate agonists.**
KAVALIERS, M. and M. HIRST 543
- Activation of dihydropyridine receptors differentially regulates temperature responses in rat.**
PILLAI, N. P. and D. H. ROSS 549
- Opiate receptor mediated hyperthermic responses in rat following Ca⁺⁺ channel antagonists.**
PILLAI, N. P. and D. H. ROSS 555
- The effects of diazepam on "fear" reactions in rats are modulated by environmental constraints on the rat's defensive repertoire.**
TREIT, D., V. M. LOLORDO and D. E. ARMSTRONG 561
- The antagonistic effects of naloxone on cycloheximide and anisomycin-induced amnesia.**
KAMEYAMA, T., T. NABESHIMA and T. KOZAWA 567

| | |
|---|-----|
| Naltrexone blocks the effects of prenatal stress on sexual behavior differentiation in male rats. | |
| WARD, O. B., E. P. MONAGHAN and I. L. WARD | 573 |
| Behavioral analysis of marijuana effects on food intake in humans. | |
| FOLTIN, R. W., J. V. BRADY and M. W. FISCHMAN | 577 |
| Barrel rotation and prostration by vasopressin and nicotine in the vestibular cerebellum. | |
| MAITI, A., K. SHAHID SALLES, S. GRASSI and L. G. ABOOD | 583 |
| Behavior and receptor changes after kainate lesioning of nodular cerebellum. | |
| MAITI, A., K. SHAHID SALLES, S. GRASSI and L. G. ABOOD | 589 |
| Potentiation of the propunishment, but not the convulsant action of the β-carboline DMCM by naltrexone. | |
| DUKA, T. and D. N. STEPHENS | 595 |
| Differences in morphine-induced antinociception and locomotor activity in mature adult and aged mice. | |
| HOSKINS, B., C. K. BURTON and I. K. HO | 599 |
| Acute ethanol effects on sensory responses of single units in the somatosensory cortex of rats during different behavioral states. | |
| CHAPIN, J. K., S. M. SORENSEN and D. J. WOODWARD | 607 |
| Effects of pimozide on emitted force, duration and rate of operant response maintained at low and high levels of required force. | |
| FOWLER, S. C., S. E. GRAMLING and R.-M. LIAO | 615 |
| Intravenous self-administration of phentermine in food-deprived rats: Effects of abrupt refeeding and saline substitution. | |
| PAPASAVA, M., G. SINGER and C. PAPASAVA | 623 |
| Effects of nalbuphine alone and in combination with tripeleminamine on rewarding brain stimulation thresholds in the rat. | |
| UNTERWALD, E. M. and C. KORNETSKY | 629 |
| Effects of scopolamine on components of delayed response performance in the rat. | |
| VISCARDI, A. P. and G. A. HEISE | 633 |
| [D-Ala²]-Methionine enkephalinamide (DALA): Characterization of antinociceptive, cardiovascular, and autonomic nervous system actions in conscious and pentobarbital-anesthetized rats. | |
| RANDICH, A. and M. F. CALLAHAN | 641 |
| Synthesis of rat brain DNA during acquisition of an appetitive task. | |
| GIUDITTA, A., C. PERRONE CAPANO, G. D'ONOFRIO, C. TONIATTI, T. MENNA and H. HYDÉN | 651 |
| Effects of marijuana smoking on subjective ratings and tobacco smoking. | |
| NEMETH-COSLETT, R., J. E. HENNINGFIELD, M. K. O'KEEFFE and R. R. GRIFFITHS | 659 |
| Influence of ambient temperature on the development and maintenance of tolerance to ethanol-induced hypothermia. | |
| LE, A. D., H. KALANT and J. M. KHANNA | 667 |
| Scopolamine impairs learning performance of rats in a 14-unit T-maze. | |
| SPANGLER, E. L., P. RIGBY and D. K. INGRAM | 673 |

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

Comparative effects of several simple carbohydrates on erythrocyte insulin receptors in obese subjects.
RIZKALLA, S. W., F. BAIGTS, F. FUMERON, B. RABILLON, P. BAYN,
A. KTORZA, D. SPEILMANN and M. APFELBAUM 681

Brief Communications

Postural asymmetry and lateralized rotation in normal rats administered apomorphine.
SZECHTMAN, H. and M. PISA 689

The effects of apomorphine on leverpress shock escape learning in rats.
MATTINGLY, B. A. 693

Naloxone's effects on intake of sequentially presented fluids.
TALANIAN, R. V., G. A. HUNTER, C. M. BEAMAN, G. L. REICHERT-
HUNTER and L. D. REID 697

CONTENTS

Articles

- The effect of ethanol and sex on radial arm maze performance in rats.**
 MAIER, D. M. and L. A. POHORECKY 703
- A behavioural and pharmacological examination of phenylethylamine-induced anorexia and hyperactivity—Comparisons with amphetamine.**
 POPPLEWELL, D. A., P. J. COFFEY, A. M. J. MONTGOMERY and
 M. J. BURTON 711
- The effects of intracranial administration of hallucinogens on operant behavior in the rat. I. Lysergic acid diethylamide.**
 MOKLER, D. J., K. W. STOUT, L. C. SHERMAN and R. H. RECH 717
- Effects of nicotine on finger tapping rate in non-smokers.**
 WEST, R. J. and M. J. JARVIS 727
- Effect of mazindol, d-amphetamine and diethylpropion on purine nucleotide binding to brown adipose tissue.**
 LUPIEN, J. R. and G. A. BRAY 733
- Hypoglycemia and hypothermia induced by ethanol: Antagonism by indomethacin.**
 MORATO, G. S., M. L. O. SOUZA, M. L. N. PIRES and J. MASUR 739
- Increase in β - and α_1 -adrenoceptor binding sites in the rat brain and in the α_1 -adrenoceptor functional sensitivity after the DSP-4-induced noradrenergic denervation.**
 MOGILNICKA, E. 743
- Effects of chlordiazepoxide and sodium valproate in two tests of spatial behaviour.**
 WILLNER, P. and K.-A. BIRBECK 747
- Effect of (1-24)adrenocorticotrophin stimulation on the rate of corticosterone synthesis by the rat adrenal cortex.**
 CAM, G. R. and J. R. BASSETT 753
- Biphasic effects of MIF-1 and Tyr-MIF-1 on apomorphine-induced stereotypy in rats.**
 HARA, C. and A. J. KASTIN 757
- Changes in brain catecholamine mechanisms following perinatal exposure to marijuana.**
 WALTERS, D. E. and L. A. CARR 763
- Differential antagonism of the behavioral depressant and hypothermic effects of 5'-(N-ethylcarboxamide) adenosine by theobromine.**
 CARNEY, J. M., W. CAO, L. LOGAN, O. M. RENNERT and T. W. SEALE 769
- Effects of cold-restraint stress on gastric ulceration and motility in rats.**
 KOO, M. W. L., C. H. CHO and C. W. OGLE 775

| | |
|---|-----|
| Interaction of tonic immobility and dexamethasone in the modulation of hippocampal 5-HT activity in rabbits. | |
| FARABOLLINI, F., L. LODI and C. LUPO | 781 |
| Reinforcing and phencyclidine-like stimulus properties of enantiomers of metazocine. | |
| SLIFER, B. L., R. L. BALSTER and E. L. MAY | 785 |
| Effects of haloperidol on the biophysical characteristics of operant responding: Implications for motor and reinforcement processes. | |
| FOWLER, S. C., M. M. LACERRA and A. ETTEBERG | 791 |
| Vasopressin-like peptides retain ethanol tolerance in the absence of changes in serotonin synthesis in limbic structures. | |
| SPEISKY, M. B. and H. KALANT | 797 |
| Action of chronically administered antidepressants on the serotonergic postsynapse in a model of depression. | |
| NAGAYAMA, H., J. AKIYOSHI and M. TOBO | 805 |
| Haloperidol induces a partial reinforcement extinction effect in rats: Implications for a dopamine involvement in food reward. | |
| ETTEBERG, A. and C. H. CAMP | 813 |
| Effect of testosterone on intermediate memory in day-old chicks. | |
| GIBBS, M. E., K. T. NG and R. J. ANDREW | 823 |
| Metabolic interactions of phencyclidine (PCP) and Δ^9-tetrahydrocannabinol (THC) in the rat. | |
| LAMÉ, M. W. and S. HUSAIN | 827 |
| Comparison of tizanidine and morphine with regard to tolerance-developing ability to antinociceptive action. | |
| NABESHIMA, T., S. YAMADA, A. SUGIMOTO, K. MATSUNO and T. KAMEYAMA | 835 |
| Fourth ventricle effects of nicotine, 2-methylpiperidine and cytosine in dogs. | |
| MARTIN, W. R., J. W. SLOAN, R. HOOK, E. KAPLAN and C. WASH | 843 |
| Dietary tryptophan supplements attenuate amphetamine self-administration in the rat. | |
| SMITH, F. L., D. S. L. YU, D. G. SMITH, A. P. LECCESE and W. H. LYNES | 849 |
| Reversible disruption of lordosis via midbrain infusions of procaine and tetrodotoxin. | |
| ROTHFELD, J. M., R. E. HARLAN, B. D. SHIVERS and D. W. PFAFF | 857 |
| Striatal dopamine activity and unilateral barpressing in rats. | |
| CHURCH, W. H., K. E. SABOL, J. B. JUSTICE, JR. and D. B. NEILL | 865 |
| Prenatal stress increases the behavioral response to serotonin agonists and alters open field behavior in the rat. | |
| PETERS, D. A. V. | 873 |
| Electroencephalographic effects of nicotine chewing gum in humans. | |
| PICKWORTH, W. B., R. I. HERNING and J. E. HENNINGFIELD | 879 |
| Effects of the putative 5-HT_{1A} receptor agonist 8-OH-2-(di-n-propylamino)tetralin on nociceptive sensitivity in mice. | |
| FASMER, O. B., O.-G. BERGE, C. POST and K. HOLE | 883 |

VOLUME INDEX

| | |
|--|-----|
| EEG alpha activity increases during transient episodes of ethanol-induced euphoria. LUKAS, S. E., J. H. MENDELSON, R. A. BENEDIKT and B. JONES | 889 |
| Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration. GUNNE, L. M., U. ANDERSSON, U. BONDESSON and P. JOHANSSON . . . | 897 |
| Alpha-adrenoceptors and monoamine contents in the cerebral cortex of the rodent <i>Macaca orientalis</i>: Effects of acute cold exposure. LAKHDAR-GHAZAL, N., L. GRONDIN, W. A. BENGELLOUN and T. A. READER | 903 |
| Effects of a chronic administration of two benzodiazepines on food intake in rats given a highly palatable diet. SEYRIG, J. A., R. FALCOU, D. BETOULLE and M. APFELBAUM | 913 |
| Time-dependent modulation by estrogen of amphetamine-induced hyperactivity in male rats. WEST, C. H. K. and R. P. MICHAEL | 919 |
| Brief Communications | |
| Amnesia produced by intracerebroventricular injections of hemicholinium-3 in mice was prevented by pretreatment with piracetam-like compounds. FRANKLIN, S. R., V. H. SETHY and A. H. TANG | 925 |
| Effects of phenobarbital in combination with phenytoin or valproic acid on the delayed-matching-to-sample performance of pigeons. KARAS, C. A., M. PICKER and A. POLING | 929 |

CONTENTS

Articles

- Repeated pemoline produces self-injurious behavior in adult and weanling rats.**
MUELLER, K., E. HOLLINGSWORTH and H. PETTIT 933
- Simultaneous brightness discrimination and reversal:
The effects of amphetamine administration in the two stages.**
WEINER, I., J. FELDON and O. BEN-SHAHAR 939
- Stimulatory effect of N-methyl aspartate on locomotor activity and transmitter release from rat
nucleus accumbens.**
HAMILTON, M. H., J. S. DE BELLEROCHE, I. M. GARDINER and
L. J. HERBERG 943
- Differential effects of α -methyl-p-tyrosine and 6-hydroxydopamine on pentylentetrazol seizures in mice.**
ABED, W. T. 949
- Brain asparaginase, ACE activity and plasma cortisol level in morphine dependent rats:
Effect of aspartic acid and naloxone.**
KOYUNCUOĞLU, H., M. GÜNGÖR, N. ENGINAR, I. HATIPOĞLU and
A. HIZAL 953
- Opiate-induced turning in rats after injection into the ventral tegmental area.**
SZEWCZAK, M. R. and M. T. SPOERLEIN 959
- Involvement of endogenous opioid peptides in fenfluramine anorexia.**
MAJEED, N. H., W. LASON, B. PRZEWŁOCKA and R. PRZEWŁOCKI 967
- Suppression of behavior by food pellet-lithium chloride pairings in squirrel monkeys.**
BERGMAN, J. and J. R. GLOWA 973
- A novel method for quantifying passive-avoidance behavior based on the exponential distribution of
step-through latencies.**
SHULZ, D., D. CHERNICHOVSKY and C. ALLWEIS 979
- Selective antagonism by clonidine of the stereotyped and non-stereotyped motor activity elicited
by atropine.**
MOLLOY, A. G., R. S. ARONSTAM and J. J. BUCCAFUSCO 985
- Clonidine reverses the behavioral and respiratory effects of continuous naloxone infusion.**
MALIN, D. H., A. G. HEMPEL, R. J. EXLEY and S. ADDINGTON 989
- Conditioned taste aversion induced by tryptamine: A temporal analysis.**
FLETCHER, P. J. 995
- Production of physical dependence in rats by drinking a morphine solution.**
LEUNG, C. M. K., C. W. OGLE and S. DAI 1001
- Opiate involvement in postpartum aggression in rats.**
KINSLEY, C. H. and R. S. BRIDGES 1007
- The development of metabolic tolerance in the alcohol-preferring P rats:
Comparison of forced and free-choice drinking of ethanol.**
LUMENG, L. and T.-K. LI 1013

| | |
|--|------|
| Differential effects of prenatal exposure to alcohol on activity and circling behavior in rats. | |
| ZIMMERBERG, B., E. P. RILEY and S. D. GLICK | 1021 |
| Tyrosine influence on amphetamine self-administration and brain catecholamines in the rat. | |
| GEIS, L. S., D. G. SMITH, F. L. SMITH, D. S. L. YU and W. H. LYNESS | 1027 |
| Decrease in d-methamphetamine sensitivity in mice due to ethanol: Apparent inhibitory and stimulatory effects of ethanol on d-methamphetamine-induced locomotor activity. | |
| KOHDA, H., M. FUNAHASHI, I. SHIKATA and H. KIMURA | 1035 |
| Further studies on nicotine-induced conditioned place preference in the rat. | |
| FUDALA, P. J. and E. T. IWAMOTO | 1041 |
| Discriminative stimulus properties of phencyclidine (PCP)-related compounds: Correlations with 3H-PCP binding potency measured autoradiographically. | |
| KOZLOWSKI, M. R., R. G. BROWNE and F. J. VINICK | 1051 |
| Comparison of anticonvulsant effect of pentobarbital and phenobarbital against seizures induced by maximal electroshock and picrotoxin in rats. | |
| MEHTA, A. K. and M. K. TICKU | 1059 |
| Cholecystokinin antagonizes morphine induced hypoactivity and hyperactivity in hamsters. | |
| SCHNUR, P., V. P. RAIGOZA, M. R. SANCHEZ and P. J. KULKOSKY | 1067 |
| Oral pyridostigmine administration in rats: Effects on thermoregulation, clinical chemistry, and performance in the heat. | |
| FRANCESCONI, R., R. HUBBARD, C. MATTHEW, N. LEVA, J. YOUNG and V. PEASE | 1071 |
| GABAergic drugs can enhance or attenuate chlordiazepoxide-induced sleep time in a heterogeneous strain of mice. | |
| McINTYRE, T. D. and H. P. ALPERN | 1077 |
| Effects of restraint stress on voluntary ethanol intake and ulcer proliferation in rats. | |
| ROCKMAN, G. E., A. HALL and G. B. GLAVIN | 1083 |
| Lead retention in blood and brain after preweaning low-level lead exposure in the rat. | |
| LIVESEY, D. J., R. G. DAWSON, P. J. LIVESEY, J. BARRETT and T. J. SPICKETT | 1089 |
| Increased dopamine metabolism in the nucleus accumbens and striatum following consumption of a nutritive meal but not a palatable non-nutritive saccharin solution. | |
| BLACKBURN, J. R., A. G. PHILLIPS, A. JAKUBOVIC and H. C. FIBIGER | 1095 |
| Single-trial conditioned place preference using intravenous morphine. | |
| BARDO, M. T. and J. L. NEISEWANDER | 1101 |
| Brief Communications | |
| Absence of clonidine-induced food intake in hamsters. | |
| KATZ, N. L., T. BRNE, J. BOLIN and R. F. SCHLEMMER, JR. | 1107 |
| Effects of Pavlovian conditioning on the ethanol withdrawal syndrome in rats. | |
| NUMAN, R. | 1111 |
| Effects of the dopamine D-2 receptor agonist, LY 171555, on radial arm maze performance in rats. | |
| LEVIN, E. D. and R. E. BOWMAN | 1117 |

CONTENTS

| | |
|--|------|
| Editorial | v |
| Articles | |
| Time-related memory effects of vasopressin analogues in rats. GAFFORI, O. J. W. and D. DE WIED | 1125 |
| Nicotine's effects on female rats' body weight: Caloric intake and physical activity. BOWEN, D. J., S. E. EURY and N. E. GRUNBERG | 1131 |
| Impairment of glycoprotein fucosylation in rat hippocampus and the consequences on memory formation. JORK, R., G. GRECKSCH and H. MATTHIES | 1137 |
| The effects of benzodiazepines in newborn rats suggest a function for type 2 receptors. FILE, S. E. and L. J. WILKS | 1145 |
| Intra-nucleus accumbens amphetamine: Dose-dependent effects on food intake. EVANS, K. R. and F. J. VACCARINO | 1149 |
| Intake of a liquid diet after 2-deoxy-D-glucose injections in rats. WATSON, P. J., D. H. RHODES, K. RHEA, J. MCKINNEY, C. HAWKINS and R. R. BARTLES | 1153 |
| Lithium effects on adjunctive alcohol consumption. I: Comparison with adjunctive water consumption. HINES, G. | 1159 |
| Lithium effects on adjunctive alcohol consumption. II: Effects of adding concurrent shock. HINES, G. | 1163 |
| A potential role of saline trials in morphine-induced place-preference conditioning. SCOLES, M. T. and S. SIEGEL | 1169 |
| Sensitization to amphetamine and tolerance to cocaine and phencyclidine stimulation in mice. KOKKINIDIS, L. | 1175 |
| Mouth versus deep airways absorption of nicotine in cigarette smokers. GORI, G. B., N. L. BENOWITZ and C. J. LYNCH | 1181 |
| Affinity for the D₂ receptor predicts neuroleptic potency in decreasing the speed of an internal clock. MECK, W. H. | 1185 |
| The schedule dependent effects of 3-quinuclidinyl benzilate on operant behavior in the rat. LIU, W.-F. and J. M. BEATON | 1191 |
| Stimulant-like effects of magnesium on aggression in mice. IZENWASSER, S. E., K. GARCIA-VALDEZ and K. M. KANTAK | 1195 |

Contents continued

| | |
|--|------|
| Environmental specificity of tolerance to morphine-induced analgesia in a terrestrial snail: Generalization of the behavioral model of tolerance. | |
| KAVALIERS, M. and M. HIRST | 1201 |
| Further studies on the dose-dependent stimulus properties of 5-methoxy-N,N-dimethyltryptamine. | |
| YOUNG, R., J. A. ROSECRANS and R. A. GLENNON | 1207 |
| Clonidine-induced sedation is not modified by single or combined neurochemical lesions of the locus coeruleus, the median and dorsal raphe nuclei. | |
| NASSIF-CAUDARELLA, S., E. KEMPF and L. VELLELY | 1211 |
| Perioral behaviors induced by cholinesterase inhibitors: A controversial animal model. | |
| RODRIGUEZ, L. A., D. E. MOSS, E. REYES and M. L. CAMARENA | 1217 |
| Medial hypothalamic serotonin: Effects on deprivation and norepinephrine-induced eating. | |
| WEISS, G. F., P. PAPADAKOS, K. KNUDSON and S. F. LEIBOWITZ | 1223 |
| A partial reinforcement extinction effect in water-reinforced rats intermittently treated with haloperidol. | |
| ETTENBERG, A. and C. H. CAMP | 1231 |
| Chlordiazepoxide and tonic immobility: A paradoxical enhancement. | |
| RAGER, D. R., G. G. GALLUP, JR. and J. W. BECKSTEAD | 1237 |
| Cigarette filter vent blocking: Effects on smoking topography and carbon monoxide exposure. | |
| ZACNY, J. P., M. L. STITZER and J. E. YINGLING | 1245 |
| Continuous pontine cholinergic microinfusion via mini-pump induces sustained alterations in rapid eye movement (REM) sleep. | |
| SHIROMANI, P. J. and W. FISHBEIN | 1253 |
| Changes in response rates and reinforcement thresholds for intracranial self-stimulation during morphine withdrawal. | |
| SCHAEFER, G. J. and R. P. MICHAEL | 1263 |
| Inherent hyporesponsiveness to methylxanthine-induced behavioral changes associated with supersensitivity to 5'-N-ethylcarboxamidoadenosine (NECA). | |
| SEALE, T. W., K. A. ABLA, W. CAO, K. M. PARKER, O. M. RENNERT and J. M. CARNEY | 1271 |
| Radio-frequency analysis of the effect of haloperidol and cyclo(leucyl-glycyl) on apomorphine-induced stereotypy. | |
| FIELDS, J. Z., L. P. GONZALEZ, L. R. MEYERSON, P. LIEBER, J. M. LEE, K. A. STEECE, F. A. DELEON-JONES and R. F. RITZMANN | 1279 |
| Dietary manipulation of ethanol preference in the Syrian Golden hamster. | |
| CUNNANE, S. C., Y.-S. HUANG and D. F. HORROBIN | 1285 |
| Dissociation of decreased numbers of muscarinic receptors from tolerance to DFP. | |
| SMOLEN, T. N., A. SMOLEN and A. C. COLLINS | 1293 |
| Brief Communications | |
| Interactions of Tyr-MIF-1 at opiate receptor sites. | |
| ZADINA, J. E. and A. J. KASTIN | 1303 |
| Exposure to amphetamine after substantia nigra lesion interferes with the process of behavioral recovery. | |
| MINTZ, M. and R. TOMER | 1307 |

1987

AVAILABLE SUPPLEMENTS

Prepayment
Required

| | | | | Price Postpaid |
|---|-------------------------------------|--------------------|---|-------------------|
| P1 PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR | | | | |
| 77.1 | Volume 3 Supplement 1, 1975 | ISBN 0-916086-00-3 | 176 pages Central Neural Control of Eating and Obesity – Edited by Matthew J. Wayner & Yutaka Oomura | \$18.50 |
| 77.2 | Volume 5 Supplement 1, 1976 | ISBN 0-916086-00-x | 192 pages The Neuropeptides: Pharmacology, Physiological Substrates and Behavioral Effects – Edited by Curt A. Sandmann, Lyle H. Miller and Abba J. Kastin | \$30.00 |
| 77.6 | Volume 11 Supplement 1, 1979 | ISBN 0-916086-07-0 | 56 pages Protracted Effects of Perinatal Drug Dependence – Edited by Theo Sonderegger and Emery Zimmermann | \$15.00 |
| 77.14 | Volume 13 Supplement 1, 1980 | ISBN 0-916086-15-1 | 312 pages Fifth Biennial International Symposium on Alcoholism – Edited by B. Tabakoff and P. L. Hoffman | \$49.25 |
| 77.15 | Volume 14 Supplement 1, 1981 | ISBN 0-916086-17-8 | 124 pages Psychopharmacology of Aggression and Social Behavior – Edited by K. A. Miczek | \$20.00 |
| 77.18 | Volume 17 Supplement 1, 1982 | ISBN 0-916086-21-6 | 60 pages Dopamine Receptors and Their Behavioral Correlates – Chairman Samuel Gershon | \$7.50 |
| 77.19 | Volume 18 Supplement 1, 1983 | ISBN 0-916086-22-4 | 600 pages First Congress of the International Society for Biomedical Research on Alcoholism – Edited by R. G. Thurman and P. L. Hoffman | \$125.00 |
| 77.21 | Volume 21 Supplement 1, 1984 | ISBN 0-916086-24-0 | 140 pages Alkali Metals: An Update – Edited by F. S. Messiha | \$30.00 |
| B2 BRAIN RESEARCH BULLETIN | | | | |
| 77.4 | Volume 4 Supplement 1, 1979 | ISBN 0-916086-04-6 | 108 pages The Anatomy of the Brain of the Bottlenose Dolphin (<i>Tursiops truncatus</i>). Rhinic Lobe (Rhinecephalon): The Archicortex – M. S. Jacobs, W. L. McFarland and P. J. Morgane | \$30.00 |
| 77.7 | Volume 5 Supplement 1, 1980 | ISBN 0-916086-08-9 | 86 pages Experimental Ulcer Produced by Behavioral Factors – Edited by Morton I. Grossman and Donald Novin | \$18.50 |
| 77.8 | Volume 5 Supplement 2, 1980 | ISBN 0-916086-09-7 | 946 pages GABA Neurotransmission: Current Developments in Physiology and Neurochemistry – Edited by Harbans Lal | \$150.00 |
| 77.9 | Volume 5 Supplement 3, 1980 | ISBN 0-916086-10-0 | 108 pages The Anatomy of the Brain of the Bottlenose Dolphin (<i>Tursiops truncatus</i>). Surface Configurations of the Telencephalon of the Bottlenose Dolphin with Comparative Anatomical Observations in Four Other Cetacean Species – Peter J. Morgane, Myron S. Jacobs and Willard L. McFarland | \$30.00 |
| 77.10 | Volume 5 Supplement 4, 1980 | ISBN 0-916086-11-9 | 206 pages Integration of Central and Peripheral Receptors in Hunger and Energy Metabolism – Edited by D. Novin and Y. Oomura | \$30.00 |
| 77.11 | Volume 5 Supplement 5, 1980 | ISBN 0-916086-12-7 | 55 pages A Stereotaxic Atlas of the Rat Olfactory System – Burton M. Slotnick and Steven Hersch | \$30.00 |
| R3 NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS | | | | |
| 77.5 | Volume 3 Supplement 1, 1979 | ISBN 0-916086-05-4 | 94 pages Blood Supply to the Brain of the Dolphin, <i>Tursiops truncatus</i> , With Comparative Observations on Special Aspects of the Cerebrovascular Supply of Other Vertebrates – W. L. McFarland, M. S. Jacobs and P. J. Morgane | \$30.00 |
| 77.12 | Volume 4 Supplement 1, 1980 | ISBN 0-916086-13-5 | 74 pages Body Energy Regulation and the Stimulation to Eat – Jacques Le Magnen and His Co-workers | \$15.00 |
| N5 NEUROBEHAVIORAL TOXICOLOGY (& TERATOLOGY) | | | | |
| 77.3 | Volume 1 Supplement 1, 1979 | ISBN 0-916086-06-2 | 222 pages Test Methods for Definition of Effects of Toxic Substances on Behavior and Neuromotor Function – Edited by I. Geller, W. C. Stebbins and M. J. Wayner | \$37.50 |
| T9 PEPTIDES | | | | |
| 77.13 | Volume 1 Supplement 1, 1980 | ISBN 0-916086-16-x | 256 pages Brain Endocrine Interaction: Neuropeptide Development and Aging – Edited by D. E. Scott and J. R. Sladek, Jr. | \$40.25 |
| 77.16 | Volume 2 Supplement 1, 1981 | ISBN 0-916086-19-4 | 170 pages Second Annual Winter Neuropeptide Conference – Edited by C. A. Sandman and L. H. Miller | \$35.00 |
| 77.17 | Volume 2 Supplement 2, 1981 | ISBN 0-916086-20-8 | 308 pages The Brain Gut Axis: A New Frontier – Edited by John H. Walsh | \$60.00 |
| 77.20 | Volume 5 Supplement 1, 1984 | ISBN 0-916086-23-2 | 288 pages Brain-Endocrine Interaction V: The Schmitt Brain Symposium – Edited by Willis K. Paull, David E. Scott and Jerald A. Mitchell | \$60.00 |
| 77.22 | Volume 6 Supplement 1, 1985 | ISBN 0-916086-25-9 | 192 pages Fifth Annual Winter Neuropeptide Conference – Edited by Lyle H. Miller | \$60.00 |
| 77.23 | Volume 6 Supplement 2, 1985 | ISBN 0-916086-26-7 | 194 pages Sixth Annual Winter Neuropeptide Conference – Edited by Gail Handelman | \$60.00 |
| 77.24 | Volume 6 Supplement 3, 1985 | | 498 pages First International Symposium on Nonmammalian Peptides – Edited by Pietro Melchiorri, Lucia Negri and Enrico Solcia | \$120.00 |
| 77.25 | Volume 7 Supplement 1, 1986 | | 294 pages Second International Symposium VIP & Related Peptides – Edited by Sami I. Said and Dominique Bataille | \$75.00 |

ANKHO International Inc

P.O. Box 380227, San Antonio, Texas 78280 U.S.A.